prettysongbk的个人主页 - 老虎社区

prettysongbk

prettysongbk

暂无个人介绍

IP属地：未知

3关注

5粉丝

0主题

0勋章

2021-11-29

I love Lulu

Lululemon Earnings: What to Watch on Dec. 9

2021-11-17

Wowwwww

抱歉，原内容已删除

2021-11-14

Ok

Pfizer Shows Its R&D Is Strong. It’s a Good Sign for the Stock.

2021-10-13

[Surprised]

Wall Street closes lower on jitters ahead of earnings, Fed minutes

2021-10-08

[Happy] [Miser] $$$$

Wall Street ends day with solid gains; investors hail U.S. debt-ceiling truce

去老虎APP查看更多动态

{"i18n":{"language":"zh_CN"},"userPageInfo":{"id":"4095759201622640","uuid":"4095759201622640","gmtCreate":1632656350100,"gmtModify":1634306747693,"name":"prettysongbk","pinyin":"prettysongbk","introduction":"","introductionEn":"","signature":"","avatar":"https://static.tigerbbs.com/88ac06c4861b9c5d61510736f27ebfb6","hat":null,"hatId":null,"hatName":null,"vip":1,"status":2,"fanSize":5,"headSize":3,"tweetSize":5,"questionSize":0,"limitLevel":999,"accountStatus":4,"level":{"id":1,"name":"萌萌虎","nameTw":"萌萌虎","represent":"呱呱坠地","factor":"评论帖子3次或发布1条主帖（非转发）","iconColor":"3C9E83","bgColor":"A2F1D9"},"themeCounts":0,"badgeCounts":0,"badges":[],"moderator":false,"superModerator":false,"manageSymbols":null,"badgeLevel":null,"boolIsFan":false,"boolIsHead":false,"favoriteSize":0,"symbols":null,"coverImage":null,"realNameVerified":null,"userBadges":[{"badgeId":"35ec162348d5460f88c959321e554969-1","templateUuid":"35ec162348d5460f88c959321e554969","name":"精英交易员","description":"证券或期货账户累计交易次数达到30次","bigImgUrl":"https://static.tigerbbs.com/ab0f87127c854ce3191a752d57b46edc","smallImgUrl":"https://static.tigerbbs.com/c9835ce48b8c8743566d344ac7a7ba8c","grayImgUrl":"https://static.tigerbbs.com/76754b53ce7a90019f132c1d2fbc698f","redirectLinkEnabled":0,"redirectLink":null,"hasAllocated":1,"isWearing":0,"stamp":null,"stampPosition":0,"hasStamp":0,"allocationCount":1,"allocatedDate":"2023.08.11","exceedPercentage":"60.75%","individualDisplayEnabled":0,"backgroundColor":null,"fontColor":null,"individualDisplaySort":0,"categoryType":1100},{"badgeId":"518b5610c3e8410da5cfad115e4b0f5a-1","templateUuid":"518b5610c3e8410da5cfad115e4b0f5a","name":"实盘交易者","description":"完成一笔实盘交易","bigImgUrl":"https://static.tigerbbs.com/2e08a1cc2087a1de93402c2c290fa65b","smallImgUrl":"https://static.tigerbbs.com/4504a6397ce1137932d56e5f4ce27166","grayImgUrl":"https://static.tigerbbs.com/4b22c79415b4cd6e3d8ebc4a0fa32604","redirectLinkEnabled":0,"redirectLink":null,"hasAllocated":1,"isWearing":0,"stamp":null,"stampPosition":0,"hasStamp":0,"allocationCount":1,"allocatedDate":"2021.12.28","exceedPercentage":null,"individualDisplayEnabled":0,"backgroundColor":null,"fontColor":null,"individualDisplaySort":0,"categoryType":1100}],"userBadgeCount":2,"currentWearingBadge":null,"individualDisplayBadges":null,"crmLevel":2,"crmLevelSwitch":0,"location":"未知","starInvestorFollowerNum":0,"starInvestorFlag":false,"starInvestorOrderShareNum":0,"subscribeStarInvestorNum":0,"ror":null,"winRationPercentage":null,"showRor":false,"investmentPhilosophy":null,"starInvestorSubscribeFlag":false},"baikeInfo":{},"tab":"post","tweets":[{"id":600868884,"gmtCreate":1638139033252,"gmtModify":1638139033252,"author":{"id":"4095759201622640","authorId":"4095759201622640","name":"prettysongbk","avatar":"https://static.tigerbbs.com/88ac06c4861b9c5d61510736f27ebfb6","crmLevel":2,"crmLevelSwitch":0,"followedFlag":false,"authorIdStr":"4095759201622640","idStr":"4095759201622640"},"themes":[],"htmlText":"I love Lulu&nbsp;","listText":"I love Lulu&nbsp;","text":"I love Lulu","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":7,"commentSize":1,"repostSize":0,"link":"https://laohu8.com/post/600868884","repostId":"1117671420","repostType":4,"repost":{"id":"1117671420","pubTimestamp":1638067569,"share":"https://www.laohu8.com/m/news/1117671420?lang=&edition=full","pubTime":"2021-11-28 10:46","market":"us","language":"en","title":"Lululemon Earnings: What to Watch on Dec. 9","url":"https://stock-news.laohu8.com/highlight/detail?id=1117671420","media":"Motley Fool","summary":"$Lululemon Athletica $ is slated to report its results for the third quarter of fiscal 2021  after the market close on Thursday, Dec. 9.Investors in the athletic apparel retailer are probably feeling optimistic about the report. Last quarter, revenue and earnings crushed Wall Street's consensus estimates, third-quarter guidance for both the top and bottom lines came in higher than analysts had been expecting, and management significantly hiked its full-year outlook for both revenue and earnings.","content":"<p><a href=\"https://laohu8.com/S/LULU\"><b>Lululemon Athletica</b>&nbsp;</a>&nbsp;is slated to report its results for the third quarter of fiscal 2021 (essentially the August-to-October period) after the market close on Thursday, Dec. 9.</p>\n<p>Investors in the athletic apparel retailer are probably feeling optimistic about the report. Last quarter, revenue and earnings crushed Wall Street's consensus estimates, third-quarter guidance for both the top and bottom lines came in higher than analysts had been expecting, and management significantly hiked its full-year outlook for both revenue and earnings. Moreover, many investors are enthused about the company's potential to be a major player in the growing home connected-fitness market, thanks to its acquisition of Mirror last year.</p>\n<p>In 2021, Lululemon stock is outrunning the market. Through Nov. 26, it's up 31.3% versus the&nbsp;<b>S&amp;P 500</b>'s 23.9% return.</p>\n<p>Here's what to watch in Lululemon's upcoming report.</p>\n<p><img src=\"https://static.tigerbbs.com/004c779d4dc4a363ecab86afd4b9cd2c\" tg-width=\"1053\" tg-height=\"339\" width=\"100%\" height=\"auto\">Investors can probably expect that the company's sales and earnings were hurt to some degree by the pandemic-driven global supply chain issues that are afflictingretailersand many other types of companies. That said, Lululemon's management has been doing a good job limiting the impact of this headwind.</p>\n<p>For context,last quarter(essentially the May-to-July period), Lululemon's sales soared 61% year over year to $1.45 billion, sprinting by the 47% growth Wall Street had expected. Growth was driven by a 142% surge in company-operated stores' revenue to $695.1 million, as many consumers returned to shopping in brick-and-mortar stores. Direct-to-consumer sales rose 8% to $597.4 million. Adjusted EPS skyrocketed 123% to $1.65, leaving the analyst consensus estimate of $1.19 in the dust.</p>\n<p>Last quarter's results were particularly strong because of the easy year-ago comparable. The year-ago period occurred early in the pandemic when consumers were cutting back their spending on non-essential products.</p>\n<p>Mirror</p>\n<p>Management hasn't been providing sales data for Mirror, \"a nearly invisible interactive home gym,\" to use Lululemon's words. But investors can expect an update on the earnings call about the company's relatively new home connected-fitness business.</p>\n<p>On last quarter's earnings call in early September, CEO Calvin McDonald said the company had Mirror shop-in-shops in 150 Lululemon stores with plans to increase that number to 200 by the holiday season. He added that the company would soon introduce Mirror to the Canadian market. Indeed, in early October, Lululemon announced that Mirror would be available in 40 of its stores across Canada and available for online purchase in the country beginning on Nov. 22.</p>\n<p>Guidance for the holiday quarter</p>\n<p>As always, Lululemon's guidance, relative to Wall Street's expectations, should be a major factor in the market's reaction to its upcoming report. Investors will likely be putting significant weight on the quarterly outlook because the holiday period is particularly important to retailers. For fiscal Q4 (essentially the November-to-January period), Wall Street is modeling for revenue to jump 28% year over year to $2.21 billion and adjusted EPS to also increase 28%, to $3.30.</p>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Lululemon Earnings: What to Watch on Dec. 9</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nLululemon Earnings: What to Watch on Dec. 9\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-11-28 10:46 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.fool.com/investing/2021/11/27/lululemon-earnings-what-to-watch-on-dec-9/><strong>Motley Fool</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Lululemon Athletica  is slated to report its results for the third quarter of fiscal 2021 (essentially the August-to-October period) after the market close on Thursday, Dec. 9.\nInvestors in the ...</p>\n\n<a href=\"https://www.fool.com/investing/2021/11/27/lululemon-earnings-what-to-watch-on-dec-9/\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"LULU":"lululemon athletica"},"source_url":"https://www.fool.com/investing/2021/11/27/lululemon-earnings-what-to-watch-on-dec-9/","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1117671420","content_text":"Lululemon Athletica  is slated to report its results for the third quarter of fiscal 2021 (essentially the August-to-October period) after the market close on Thursday, Dec. 9.\nInvestors in the athletic apparel retailer are probably feeling optimistic about the report. Last quarter, revenue and earnings crushed Wall Street's consensus estimates, third-quarter guidance for both the top and bottom lines came in higher than analysts had been expecting, and management significantly hiked its full-year outlook for both revenue and earnings. Moreover, many investors are enthused about the company's potential to be a major player in the growing home connected-fitness market, thanks to its acquisition of Mirror last year.\nIn 2021, Lululemon stock is outrunning the market. Through Nov. 26, it's up 31.3% versus the S&P 500's 23.9% return.\nHere's what to watch in Lululemon's upcoming report.\nInvestors can probably expect that the company's sales and earnings were hurt to some degree by the pandemic-driven global supply chain issues that are afflictingretailersand many other types of companies. That said, Lululemon's management has been doing a good job limiting the impact of this headwind.\nFor context,last quarter(essentially the May-to-July period), Lululemon's sales soared 61% year over year to $1.45 billion, sprinting by the 47% growth Wall Street had expected. Growth was driven by a 142% surge in company-operated stores' revenue to $695.1 million, as many consumers returned to shopping in brick-and-mortar stores. Direct-to-consumer sales rose 8% to $597.4 million. Adjusted EPS skyrocketed 123% to $1.65, leaving the analyst consensus estimate of $1.19 in the dust.\nLast quarter's results were particularly strong because of the easy year-ago comparable. The year-ago period occurred early in the pandemic when consumers were cutting back their spending on non-essential products.\nMirror\nManagement hasn't been providing sales data for Mirror, \"a nearly invisible interactive home gym,\" to use Lululemon's words. But investors can expect an update on the earnings call about the company's relatively new home connected-fitness business.\nOn last quarter's earnings call in early September, CEO Calvin McDonald said the company had Mirror shop-in-shops in 150 Lululemon stores with plans to increase that number to 200 by the holiday season. He added that the company would soon introduce Mirror to the Canadian market. Indeed, in early October, Lululemon announced that Mirror would be available in 40 of its stores across Canada and available for online purchase in the country beginning on Nov. 22.\nGuidance for the holiday quarter\nAs always, Lululemon's guidance, relative to Wall Street's expectations, should be a major factor in the market's reaction to its upcoming report. Investors will likely be putting significant weight on the quarterly outlook because the holiday period is particularly important to retailers. For fiscal Q4 (essentially the November-to-January period), Wall Street is modeling for revenue to jump 28% year over year to $2.21 billion and adjusted EPS to also increase 28%, to $3.30.","news_type":1},"isVote":1,"tweetType":1,"viewCount":651,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},{"id":871443313,"gmtCreate":1637108445809,"gmtModify":1637108445938,"author":{"id":"4095759201622640","authorId":"4095759201622640","name":"prettysongbk","avatar":"https://static.tigerbbs.com/88ac06c4861b9c5d61510736f27ebfb6","crmLevel":2,"crmLevelSwitch":0,"followedFlag":false,"authorIdStr":"4095759201622640","idStr":"4095759201622640"},"themes":[],"htmlText":"Wowwwww","listText":"Wowwwww","text":"Wowwwww","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":5,"commentSize":1,"repostSize":0,"link":"https://laohu8.com/post/871443313","repostId":"2184847528","repostType":4,"isVote":1,"tweetType":1,"viewCount":551,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},{"id":873393299,"gmtCreate":1636854438424,"gmtModify":1636854438424,"author":{"id":"4095759201622640","authorId":"4095759201622640","name":"prettysongbk","avatar":"https://static.tigerbbs.com/88ac06c4861b9c5d61510736f27ebfb6","crmLevel":2,"crmLevelSwitch":0,"followedFlag":false,"authorIdStr":"4095759201622640","idStr":"4095759201622640"},"themes":[],"htmlText":"Ok","listText":"Ok","text":"Ok","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":4,"commentSize":1,"repostSize":0,"link":"https://laohu8.com/post/873393299","repostId":"1102251183","repostType":4,"repost":{"id":"1102251183","pubTimestamp":1636772424,"share":"https://www.laohu8.com/m/news/1102251183?lang=&edition=full","pubTime":"2021-11-13 11:00","market":"us","language":"en","title":"Pfizer Shows Its R&D Is Strong. It’s a Good Sign for the Stock.","url":"https://stock-news.laohu8.com/highlight/detail?id=1102251183","media":"Barrons","summary":"Pfizer’s chief scientific officer, Mikael Dolsten, sounded giddy when reached via telephone early Mo","content":"<p>Pfizer’s&nbsp;chief scientific officer, Mikael Dolsten, sounded giddy when reached via telephone early Monday morning. It was just days after his company knocked the socks off the market with the news that its Covid-19 antiviral had cut the risk of hospitalization by 89% in high-risk adults.</p>\n<p>“It can’t be just a random thing, that you’re able to beat this type of world record and get a grand slam at the same time by chance,” Dolsten said, scrambling sports metaphors as he sought to illustrate the magnitude of Pfizer’s twin wins: the development of a stunningly effective Covid-19 vaccine in just 10 months, followed a year later by the development of a similarly stunning Covid-19 antiviral.</p>\n<p>Two years ago, Pfizer (ticker: PFE) CEO Albert Bourla asked investors to take a big gamble on the research-and-development operation that Dolsten has rebuilt over the course of more than a decade. That bet is looking smarter than ever.</p>\n<p>Bourla has gotten rid of Pfizer’s off-patent drugs division and the last of its consumer health products, leaving behind a pure-play biopharma company that will live or die on the strength of Dolsten’s science.</p>\n<p>In a cover story in November 2019, <i>Barron’s</i> argued that Bourla and Dolsten could pull it off.</p>\n<p>The new antiviral data reaffirms the case for Pfizer that <i>Barron’s</i> made two years ago. Continuing to profit off the pandemic, however, brings new risks, as criticism grows over the global inequity in vaccine distribution. Low-income nations account for less than 1% of the more than seven billion doses administered worldwide. If distribution of Pfizer’s antiviral continues to favor wealthy nations, the company’s stock could ultimately suffer.</p>\n<p>Pfizer’s shares surged 10.9% the day the data came out, their best daily showing in at least 20 years. Still, with the stock now changing hands at around $50, investors continue to undervalue the company. Investors are pricing Pfizer at 12 times next year’s expected earnings, cheaper than peers like&nbsp;Johnson &amp; Johnson&nbsp;(JNJ) and&nbsp;Eli Lilly&nbsp;(LLY).</p>\n<p>The Pfizer discount can be attributed to concerns over the patent cliff the drugmaker faces at the end of the decade. The company stands to lose exclusivity over a handful of drugs that bring in billions in annual revenue.</p>\n<p>The worries are legitimate, but Pfizer’s scientific coup should give investors confidence that the company’s science can carry it safely over that cliff. It may take time for the market to catch up, but for long-term investors, it’s a promising opportunity.</p>\n<p>The success of the antiviral is the best illustration yet of Pfizer’s scientific prowess.</p>\n<p>While Pfizer’s Covid-19 vaccine came out of the labs of the German biotech&nbsp;BioNTech&nbsp;(BNTX), the new Covid-19 antiviral was whipped up by what Dolsten called a “dream team” of scientists at Pfizer’s own labs across the Northeast U.S.</p>\n<p>In the earliest days of the pandemic, Pfizer split its efforts between its collaboration with BioNTech on the vaccine and its quest for a Covid-19 pill. The vaccine effort operated on a huge scale; Dolsten called it a “mega team” that spanned the Atlantic.</p>\n<p>The antiviral project was a much smaller operation—a group of Pfizer experts operating with resources left over from the vaccine push.</p>\n<p>“The small molecule was more like a nimble, laser-focused, high-end team, with rather moderate resources,” Dolsten said.</p>\n<p>Dolsten gathered some of Pfizer’s most experienced scientists to work on the antiviral project, including its head of medicine design, Charlotte Allerton. The scientists started with work Pfizer had done years ago on a type of antiviral called a protease inhibitor.</p>\n<p>“[Pfizer’s] pharmaceutical R&amp;D is better than people had thought.”</p>\n<p>The protease inhibitors in the Pfizer library, however, had been administered intravenously, and had not worked well when delivered orally. The team had to figure out how to adapt the drugs to oral administration, a substantial undertaking.</p>\n<p>“They had to really create a lot of new chemistry,” Dolsten said. The scientists created 600 compounds to nail down the right drug, a process that might normally take years, and which they accomplished in a matter of months. “Four years turned into four months here,” he said.</p>\n<p>Pfizer started testing the pill in humans in March. It is now running a number of Phase 2/3 trials of the drug, including one for patients who are high risk, one for patients not high risk, and one as a prophylaxis for patients who have been exposed to the virus but aren’t yet sick. In the first readout, the drug looked substantially more effective than the Covid treatment pill from&nbsp;Merck&nbsp;(MRK).</p>\n<p>“It definitely helps prove the point that [Pfizer’s] pharmaceutical R&amp;D is better than people had thought,” says Louise Chen, an analyst at Cantor Fitzgerald, who has an Overweight rating and a $61 price target on the stock.</p>\n<p>Chen says that she doesn’t expect investors to come around to her way of thinking until there is more clarity on the durability of Covid-19 vaccine and pill sales, and the rest of the pipeline gets proved out.</p>\n<p>“There is not one event that I think will trigger a re-rating of the stock at the next level,” she says. “Until those things play out, I don’t think that it necessarily will.”</p>\n<p>That makes a bet on Pfizer a long-term play. In the meantime, the experience of&nbsp;Moderna&nbsp;(MRNA) in recent weeks is highlighting the potential for the vaccine makers to come under scrutiny over unequal distribution of vaccines.</p>\n<p>Biden administration officials have been increasingly frustrated with Moderna, calling on the company to ramp up production so it can offer more doses at not-for-profit prices to low-income countries, with one top official calling on the company to “step up.”</p>\n<p>Moderna shares are down more than 40% over the past three months.</p>\n<p>As the pandemic persists, Pfizer risks eroding the enormous goodwill it earned roughly a year ago when it introduced its Covid-19 vaccine. Earlier this month, Pfizer CEO Bourla blamed low-income countries for unfair vaccine distribution, telling <i>Barron’s</i> that it was their fault for not placing orders. Pfizer has sold a billion vaccine doses to the U.S. at a not-for-profit price to donate to poor countries, and says that a total of at least two billion doses will be delivered to low- and middle-income nations by the end of next year.</p>\n<p>When it comes to antivirals, Pfizer has said only that it will offer tiered pricing for poorer nations, the same approach it has taken with its vaccine.</p>\n<p>That contrasts sharply with Merck’s plan to make its own Covid-19 pill available to poor countries. Merck has signed a deal with a United Nations-backed group that will allow its pill to be licensed globally, with no royalties paid to Merck.</p>\n<p>Dolsten said that Pfizer is looking into licensing its pill under a similar mechanism as Merck’s. “We will look at those options,” he said. “By no means have we said we would do something different. We just want to make sure whoever will be involved gets the advice and skill to do this.”</p>\n<p>Such a step couldn’t come soon enough. Late last month, activists protested outside Bourla’s home, calling on Pfizer to share its vaccine manufacturing technology and to fill orders from low-income countries ahead of those from wealthy countries.</p>\n<p>An aggressive plan to share its antiviral would help stave off such criticism, keeping Pfizer in the relative good graces of Washington and allowing its impressive science to continue to drive the stock higher.</p>","source":"lsy1601382232898","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Pfizer Shows Its R&D Is Strong. It’s a Good Sign for the Stock.</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nPfizer Shows Its R&D Is Strong. It’s a Good Sign for the Stock.\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-11-13 11:00 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.barrons.com/articles/buy-pfizer-stock-covid-19-51636674652?mod=hp_LEAD_1><strong>Barrons</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Pfizer’s chief scientific officer, Mikael Dolsten, sounded giddy when reached via telephone early Monday morning. It was just days after his company knocked the socks off the market with the news that...</p>\n\n<a href=\"https://www.barrons.com/articles/buy-pfizer-stock-covid-19-51636674652?mod=hp_LEAD_1\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{},"source_url":"https://www.barrons.com/articles/buy-pfizer-stock-covid-19-51636674652?mod=hp_LEAD_1","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1102251183","content_text":"Pfizer’s chief scientific officer, Mikael Dolsten, sounded giddy when reached via telephone early Monday morning. It was just days after his company knocked the socks off the market with the news that its Covid-19 antiviral had cut the risk of hospitalization by 89% in high-risk adults.\n“It can’t be just a random thing, that you’re able to beat this type of world record and get a grand slam at the same time by chance,” Dolsten said, scrambling sports metaphors as he sought to illustrate the magnitude of Pfizer’s twin wins: the development of a stunningly effective Covid-19 vaccine in just 10 months, followed a year later by the development of a similarly stunning Covid-19 antiviral.\nTwo years ago, Pfizer (ticker: PFE) CEO Albert Bourla asked investors to take a big gamble on the research-and-development operation that Dolsten has rebuilt over the course of more than a decade. That bet is looking smarter than ever.\nBourla has gotten rid of Pfizer’s off-patent drugs division and the last of its consumer health products, leaving behind a pure-play biopharma company that will live or die on the strength of Dolsten’s science.\nIn a cover story in November 2019, Barron’s argued that Bourla and Dolsten could pull it off.\nThe new antiviral data reaffirms the case for Pfizer that Barron’s made two years ago. Continuing to profit off the pandemic, however, brings new risks, as criticism grows over the global inequity in vaccine distribution. Low-income nations account for less than 1% of the more than seven billion doses administered worldwide. If distribution of Pfizer’s antiviral continues to favor wealthy nations, the company’s stock could ultimately suffer.\nPfizer’s shares surged 10.9% the day the data came out, their best daily showing in at least 20 years. Still, with the stock now changing hands at around $50, investors continue to undervalue the company. Investors are pricing Pfizer at 12 times next year’s expected earnings, cheaper than peers like Johnson & Johnson (JNJ) and Eli Lilly (LLY).\nThe Pfizer discount can be attributed to concerns over the patent cliff the drugmaker faces at the end of the decade. The company stands to lose exclusivity over a handful of drugs that bring in billions in annual revenue.\nThe worries are legitimate, but Pfizer’s scientific coup should give investors confidence that the company’s science can carry it safely over that cliff. It may take time for the market to catch up, but for long-term investors, it’s a promising opportunity.\nThe success of the antiviral is the best illustration yet of Pfizer’s scientific prowess.\nWhile Pfizer’s Covid-19 vaccine came out of the labs of the German biotech BioNTech (BNTX), the new Covid-19 antiviral was whipped up by what Dolsten called a “dream team” of scientists at Pfizer’s own labs across the Northeast U.S.\nIn the earliest days of the pandemic, Pfizer split its efforts between its collaboration with BioNTech on the vaccine and its quest for a Covid-19 pill. The vaccine effort operated on a huge scale; Dolsten called it a “mega team” that spanned the Atlantic.\nThe antiviral project was a much smaller operation—a group of Pfizer experts operating with resources left over from the vaccine push.\n“The small molecule was more like a nimble, laser-focused, high-end team, with rather moderate resources,” Dolsten said.\nDolsten gathered some of Pfizer’s most experienced scientists to work on the antiviral project, including its head of medicine design, Charlotte Allerton. The scientists started with work Pfizer had done years ago on a type of antiviral called a protease inhibitor.\n“[Pfizer’s] pharmaceutical R&D is better than people had thought.”\nThe protease inhibitors in the Pfizer library, however, had been administered intravenously, and had not worked well when delivered orally. The team had to figure out how to adapt the drugs to oral administration, a substantial undertaking.\n“They had to really create a lot of new chemistry,” Dolsten said. The scientists created 600 compounds to nail down the right drug, a process that might normally take years, and which they accomplished in a matter of months. “Four years turned into four months here,” he said.\nPfizer started testing the pill in humans in March. It is now running a number of Phase 2/3 trials of the drug, including one for patients who are high risk, one for patients not high risk, and one as a prophylaxis for patients who have been exposed to the virus but aren’t yet sick. In the first readout, the drug looked substantially more effective than the Covid treatment pill from Merck (MRK).\n“It definitely helps prove the point that [Pfizer’s] pharmaceutical R&D is better than people had thought,” says Louise Chen, an analyst at Cantor Fitzgerald, who has an Overweight rating and a $61 price target on the stock.\nChen says that she doesn’t expect investors to come around to her way of thinking until there is more clarity on the durability of Covid-19 vaccine and pill sales, and the rest of the pipeline gets proved out.\n“There is not one event that I think will trigger a re-rating of the stock at the next level,” she says. “Until those things play out, I don’t think that it necessarily will.”\nThat makes a bet on Pfizer a long-term play. In the meantime, the experience of Moderna (MRNA) in recent weeks is highlighting the potential for the vaccine makers to come under scrutiny over unequal distribution of vaccines.\nBiden administration officials have been increasingly frustrated with Moderna, calling on the company to ramp up production so it can offer more doses at not-for-profit prices to low-income countries, with one top official calling on the company to “step up.”\nModerna shares are down more than 40% over the past three months.\nAs the pandemic persists, Pfizer risks eroding the enormous goodwill it earned roughly a year ago when it introduced its Covid-19 vaccine. Earlier this month, Pfizer CEO Bourla blamed low-income countries for unfair vaccine distribution, telling Barron’s that it was their fault for not placing orders. Pfizer has sold a billion vaccine doses to the U.S. at a not-for-profit price to donate to poor countries, and says that a total of at least two billion doses will be delivered to low- and middle-income nations by the end of next year.\nWhen it comes to antivirals, Pfizer has said only that it will offer tiered pricing for poorer nations, the same approach it has taken with its vaccine.\nThat contrasts sharply with Merck’s plan to make its own Covid-19 pill available to poor countries. Merck has signed a deal with a United Nations-backed group that will allow its pill to be licensed globally, with no royalties paid to Merck.\nDolsten said that Pfizer is looking into licensing its pill under a similar mechanism as Merck’s. “We will look at those options,” he said. “By no means have we said we would do something different. We just want to make sure whoever will be involved gets the advice and skill to do this.”\nSuch a step couldn’t come soon enough. Late last month, activists protested outside Bourla’s home, calling on Pfizer to share its vaccine manufacturing technology and to fill orders from low-income countries ahead of those from wealthy countries.\nAn aggressive plan to share its antiviral would help stave off such criticism, keeping Pfizer in the relative good graces of Washington and allowing its impressive science to continue to drive the stock higher.","news_type":1},"isVote":1,"tweetType":1,"viewCount":593,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},{"id":822982110,"gmtCreate":1634085093240,"gmtModify":1634085093353,"author":{"id":"4095759201622640","authorId":"4095759201622640","name":"prettysongbk","avatar":"https://static.tigerbbs.com/88ac06c4861b9c5d61510736f27ebfb6","crmLevel":2,"crmLevelSwitch":0,"followedFlag":false,"authorIdStr":"4095759201622640","idStr":"4095759201622640"},"themes":[],"htmlText":"[Surprised]&nbsp;","listText":"[Surprised]&nbsp;","text":"[Surprised]","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":8,"commentSize":1,"repostSize":0,"link":"https://laohu8.com/post/822982110","repostId":"2175132100","repostType":4,"repost":{"id":"2175132100","weMediaInfo":{"introduction":"Reuters.com brings you the latest news from around the world, covering breaking news in markets, business, politics, entertainment and technology","home_visible":1,"media_name":"Reuters","id":"1036604489","head_image":"https://static.tigerbbs.com/443ce19704621c837795676028cec868"},"pubTimestamp":1634079953,"share":"https://www.laohu8.com/m/news/2175132100?lang=&edition=full","pubTime":"2021-10-13 07:05","market":"us","language":"en","title":"Wall Street closes lower on jitters ahead of earnings, Fed minutes","url":"https://stock-news.laohu8.com/highlight/detail?id=2175132100","media":"Reuters","summary":"NEW YORK, Oct 12 (Reuters) - U.S. stocks finished lower on Tuesday, extending losses late as investo","content":"<p>NEW YORK, Oct 12 (Reuters) - U.S. stocks finished lower on Tuesday, extending losses late as investors grew more jittery in the run up to third-quarter earnings, while a jump in Tesla shares helped support the market.</p>\n<p>Adding to investor caution, the Federal Reserve is expected to release minutes on Wednesday from its last policy meeting, which market participants will scour for hints about when the U.S. central bank could begin tapering its massive bond-buying program.</p>\n<p>All three major U.S. stock indexes ended in the red with the Dow down the most, weighed by healthcare&nbsp;and industrials .</p>\n<p>Earnings unofficially kick off this week with results from JPMorgan Chase &amp; Co&nbsp;on Wednesday and other banks to follow. JPMorgan's shares shed 0.8% on the day, while the S&amp;P 500 banks index&nbsp;edged down 0.6%.</p>\n<p>Analysts expect to see strong U.S. profit growth for the third quarter. But a number of companies have warned of issues and investors are worried about how supply chain problems and higher prices will affect businesses emerging from the coronavirus pandemic.</p>\n<p>\"For the most part, institutional portfolio managers are of the view - let's see what earnings look like and how much of a negative impact is being seen from shortages, higher rates and supply chain bottlenecks,\" said Michael James, managing director of equity trading at Wedbush Securities in Los Angeles.</p>\n<p>\"A lot of those factors are currently reflected where equity prices are now.\"</p>\n<p>The Dow Jones Industrial Average&nbsp;fell 117.72 points, or 0.34%, to 34,378.34, the S&amp;P 500&nbsp;lost 10.54 points, or 0.24%, to 4,350.65 and the Nasdaq Composite&nbsp;dropped 20.28 points, or 0.14%, to 14,465.93.</p>\n<p>Six of the 11 major sectors of the S&amp;P 500 ended the session in the red, with communications services&nbsp;suffering the steepest percentage loss.</p>\n<p>Tesla&nbsp;advanced 1.7% after data showed the electric vehicle maker sold 56,006 China-made vehicles in September, the highest since it started production in Shanghai about two years ago. The company's shares provided the biggest boost to the S&amp;P 500 and the Nasdaq.</p>\n<p>Shares of American Airlines Group&nbsp;rose 0.8% after the company estimated a smaller-than-expected adjusted loss for the third quarter and signaled improved bookings for the rest of the year.</p>\n<p>MGM Resorts&nbsp;surged 9.6% after of Credit Suisse upgraded the stock to \"outperform\" from \"neutral.\"</p>\n<p>Nike Inc&nbsp;gained 2.0% after Goldman Sachs initiated coverage with a \"buy\" recommendation.</p>\n<p>Investors also weighed comments from Fed Vice Chair Richard Clarida, who said the central bank has all but met its employment goal for reducing its bond buying program.</p>\n<p>U.S. data showed the labor market remained tight, with a record number of Americans quitting their jobs and job vacancies numbering more than 10 million, stoking inflation fears as employers hike wages to attract and retain workers.</p>\n<p>Wednesday's consumer price index report will attract attention from investors seeking clues about inflation.</p>\n<p>Advancing issues outnumbered declining ones on the NYSE by a 1.38-to-1 ratio; on Nasdaq, a 1.42-to-1 ratio favored advancers.</p>\n<p>The S&amp;P 500 posted 10 new 52-week highs and 10 new lows; the Nasdaq Composite recorded 46 new highs and 94 new lows.</p>\n<p>Volume on U.S. exchanges was 9.17 billion shares, compared with the 10.80 billion average over the last 20 trading days.</p>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Wall Street closes lower on jitters ahead of earnings, Fed minutes</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nWall Street closes lower on jitters ahead of earnings, Fed minutes\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1036604489\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/443ce19704621c837795676028cec868);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Reuters </p>\n<p class=\"h-time\">2021-10-13 07:05</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>NEW YORK, Oct 12 (Reuters) - U.S. stocks finished lower on Tuesday, extending losses late as investors grew more jittery in the run up to third-quarter earnings, while a jump in Tesla shares helped support the market.</p>\n<p>Adding to investor caution, the Federal Reserve is expected to release minutes on Wednesday from its last policy meeting, which market participants will scour for hints about when the U.S. central bank could begin tapering its massive bond-buying program.</p>\n<p>All three major U.S. stock indexes ended in the red with the Dow down the most, weighed by healthcare&nbsp;and industrials .</p>\n<p>Earnings unofficially kick off this week with results from JPMorgan Chase &amp; Co&nbsp;on Wednesday and other banks to follow. JPMorgan's shares shed 0.8% on the day, while the S&amp;P 500 banks index&nbsp;edged down 0.6%.</p>\n<p>Analysts expect to see strong U.S. profit growth for the third quarter. But a number of companies have warned of issues and investors are worried about how supply chain problems and higher prices will affect businesses emerging from the coronavirus pandemic.</p>\n<p>\"For the most part, institutional portfolio managers are of the view - let's see what earnings look like and how much of a negative impact is being seen from shortages, higher rates and supply chain bottlenecks,\" said Michael James, managing director of equity trading at Wedbush Securities in Los Angeles.</p>\n<p>\"A lot of those factors are currently reflected where equity prices are now.\"</p>\n<p>The Dow Jones Industrial Average&nbsp;fell 117.72 points, or 0.34%, to 34,378.34, the S&amp;P 500&nbsp;lost 10.54 points, or 0.24%, to 4,350.65 and the Nasdaq Composite&nbsp;dropped 20.28 points, or 0.14%, to 14,465.93.</p>\n<p>Six of the 11 major sectors of the S&amp;P 500 ended the session in the red, with communications services&nbsp;suffering the steepest percentage loss.</p>\n<p>Tesla&nbsp;advanced 1.7% after data showed the electric vehicle maker sold 56,006 China-made vehicles in September, the highest since it started production in Shanghai about two years ago. The company's shares provided the biggest boost to the S&amp;P 500 and the Nasdaq.</p>\n<p>Shares of American Airlines Group&nbsp;rose 0.8% after the company estimated a smaller-than-expected adjusted loss for the third quarter and signaled improved bookings for the rest of the year.</p>\n<p>MGM Resorts&nbsp;surged 9.6% after of Credit Suisse upgraded the stock to \"outperform\" from \"neutral.\"</p>\n<p>Nike Inc&nbsp;gained 2.0% after Goldman Sachs initiated coverage with a \"buy\" recommendation.</p>\n<p>Investors also weighed comments from Fed Vice Chair Richard Clarida, who said the central bank has all but met its employment goal for reducing its bond buying program.</p>\n<p>U.S. data showed the labor market remained tight, with a record number of Americans quitting their jobs and job vacancies numbering more than 10 million, stoking inflation fears as employers hike wages to attract and retain workers.</p>\n<p>Wednesday's consumer price index report will attract attention from investors seeking clues about inflation.</p>\n<p>Advancing issues outnumbered declining ones on the NYSE by a 1.38-to-1 ratio; on Nasdaq, a 1.42-to-1 ratio favored advancers.</p>\n<p>The S&amp;P 500 posted 10 new 52-week highs and 10 new lows; the Nasdaq Composite recorded 46 new highs and 94 new lows.</p>\n<p>Volume on U.S. exchanges was 9.17 billion shares, compared with the 10.80 billion average over the last 20 trading days.</p>\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{},"is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"2175132100","content_text":"NEW YORK, Oct 12 (Reuters) - U.S. stocks finished lower on Tuesday, extending losses late as investors grew more jittery in the run up to third-quarter earnings, while a jump in Tesla shares helped support the market.\nAdding to investor caution, the Federal Reserve is expected to release minutes on Wednesday from its last policy meeting, which market participants will scour for hints about when the U.S. central bank could begin tapering its massive bond-buying program.\nAll three major U.S. stock indexes ended in the red with the Dow down the most, weighed by healthcare and industrials .\nEarnings unofficially kick off this week with results from JPMorgan Chase & Co on Wednesday and other banks to follow. JPMorgan's shares shed 0.8% on the day, while the S&P 500 banks index edged down 0.6%.\nAnalysts expect to see strong U.S. profit growth for the third quarter. But a number of companies have warned of issues and investors are worried about how supply chain problems and higher prices will affect businesses emerging from the coronavirus pandemic.\n\"For the most part, institutional portfolio managers are of the view - let's see what earnings look like and how much of a negative impact is being seen from shortages, higher rates and supply chain bottlenecks,\" said Michael James, managing director of equity trading at Wedbush Securities in Los Angeles.\n\"A lot of those factors are currently reflected where equity prices are now.\"\nThe Dow Jones Industrial Average fell 117.72 points, or 0.34%, to 34,378.34, the S&P 500 lost 10.54 points, or 0.24%, to 4,350.65 and the Nasdaq Composite dropped 20.28 points, or 0.14%, to 14,465.93.\nSix of the 11 major sectors of the S&P 500 ended the session in the red, with communications services suffering the steepest percentage loss.\nTesla advanced 1.7% after data showed the electric vehicle maker sold 56,006 China-made vehicles in September, the highest since it started production in Shanghai about two years ago. The company's shares provided the biggest boost to the S&P 500 and the Nasdaq.\nShares of American Airlines Group rose 0.8% after the company estimated a smaller-than-expected adjusted loss for the third quarter and signaled improved bookings for the rest of the year.\nMGM Resorts surged 9.6% after of Credit Suisse upgraded the stock to \"outperform\" from \"neutral.\"\nNike Inc gained 2.0% after Goldman Sachs initiated coverage with a \"buy\" recommendation.\nInvestors also weighed comments from Fed Vice Chair Richard Clarida, who said the central bank has all but met its employment goal for reducing its bond buying program.\nU.S. data showed the labor market remained tight, with a record number of Americans quitting their jobs and job vacancies numbering more than 10 million, stoking inflation fears as employers hike wages to attract and retain workers.\nWednesday's consumer price index report will attract attention from investors seeking clues about inflation.\nAdvancing issues outnumbered declining ones on the NYSE by a 1.38-to-1 ratio; on Nasdaq, a 1.42-to-1 ratio favored advancers.\nThe S&P 500 posted 10 new 52-week highs and 10 new lows; the Nasdaq Composite recorded 46 new highs and 94 new lows.\nVolume on U.S. exchanges was 9.17 billion shares, compared with the 10.80 billion average over the last 20 trading days.","news_type":1},"isVote":1,"tweetType":1,"viewCount":599,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},{"id":823566029,"gmtCreate":1633649918275,"gmtModify":1633649918367,"author":{"id":"4095759201622640","authorId":"4095759201622640","name":"prettysongbk","avatar":"https://static.tigerbbs.com/88ac06c4861b9c5d61510736f27ebfb6","crmLevel":2,"crmLevelSwitch":0,"followedFlag":false,"authorIdStr":"4095759201622640","idStr":"4095759201622640"},"themes":[],"htmlText":"[Happy]&nbsp;[Miser]&nbsp;$$$$","listText":"[Happy]&nbsp;[Miser]&nbsp;$$$$","text":"[Happy] [Miser] $$$$","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":5,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/823566029","repostId":"1163018074","repostType":4,"repost":{"id":"1163018074","weMediaInfo":{"introduction":"Reuters.com brings you the latest news from around the world, covering breaking news in markets, business, politics, entertainment and technology","home_visible":1,"media_name":"Reuters","id":"1036604489","head_image":"https://static.tigerbbs.com/443ce19704621c837795676028cec868"},"pubTimestamp":1633646971,"share":"https://www.laohu8.com/m/news/1163018074?lang=&edition=full","pubTime":"2021-10-08 06:49","market":"us","language":"en","title":"Wall Street ends day with solid gains; investors hail U.S. debt-ceiling truce","url":"https://stock-news.laohu8.com/highlight/detail?id=1163018074","media":"Reuters","summary":"U.S. Senate rushes to advance $480 bln debt-limit increase\nU.S. weekly jobless claims fall sharply\nC","content":"<ul>\n <li>U.S. Senate rushes to advance $480 bln debt-limit increase</li>\n <li>U.S. weekly jobless claims fall sharply</li>\n <li>Consumer discretionary and materials lead sectors</li>\n <li>Levi Strauss shares soar after profit beat</li>\n <li>Indexes jump: Dow 0.98%, S&amp;P 0.83%, Nasdaq 1.05%</li>\n</ul>\n<p>Oct 7 (Reuters) - Wall Street ended sharply higher on Thursday in a broad-based rally led by Big Tech, as a truce in the debt-ceiling standoff in the U.S. Congress relieved concerns of a possible government debt default this month.</p>\n<p>Mega-cap stocks jumped with Apple Inc&nbsp;up 0.9% and Amazon.com Inc&nbsp;rising 1.2%, the biggest boosts to the S&amp;P 500 and Nasdaq. Tesla&nbsp;and Google-parent Alphabet&nbsp;both rose more than 1%.</p>\n<p>The U.S. Senate took a step toward passing a $480 billion increase in Treasury Department borrowing authority, which would put off another partisan showdown until December.</p>\n<p>Uncertainty over the debt-ceiling negotiations was one concern investors cited in September as the S&amp;P 500 logged its biggest monthly percentage drop since the onset of the coronavirus pandemic in March 2020.</p>\n<p>\"Today's (market) is driven by a slight move in Washington towards rationality about being able to pay their bills, write some checks,\" said Kim Forrest, chief investment officer at Bokeh Capital Partners in Pittsburgh.</p>\n<p>Meanwhile, data showed the number of Americans filing new claims for jobless benefits dropped last week by the most in three months, suggesting the labor market recovery was regaining momentum as the latest wave of COVID-19 infections began to subside.</p>\n<p>The closely watched monthly U.S. jobs report is due on Friday.</p>\n<p>“Today’s numbers reinforce the expectation that employment will take a significant step up in the coming months, and I think that’s positive for the economy,” said Brad Neuman, director of market strategy at Alger.</p>\n<p>\"The market climbed its wall of worry today as fears of a debt-ceiling impasse receded and hopes for an acceleration in employment gains were reinforced.”</p>\n<p>The Dow Jones Industrial Average&nbsp;rose 0.98% to end at 34,754.94 points, while the S&amp;P 500&nbsp;gained 0.83% to 4,399.76.</p>\n<p>The Nasdaq Composite&nbsp;climbed 1.05% to 14,654.02.</p>\n<p>The S&amp;P 500 materials index&nbsp;jumped 1.35% and the consumer discretionary index&nbsp;rallied 1.50%, both leading among 11 sectors.</p>\n<p>U.S.-traded Chinese stocks Alibaba Group Holding&nbsp;and Tencent Holdings&nbsp;each surged about 8% as concerns around U.S.-Sino trade relations and Evergrande's&nbsp;debt crisis appeared to ease.</p>\n<p>Investors will watch third-quarter earnings reports that start to arrive in earnest next week. Analysts on average estimate S&amp;P 500 companies' earnings per share rose 29% in the third quarter, according to Refinitiv.</p>\n<p>Levi Strauss &amp; Co&nbsp;shares jumped 8.5% after the jeans maker beat third-quarter revenue and profit estimates.</p>\n<p>Volume on U.S. exchanges was 10.1 billion shares, compared with the 11 billion average over the last 20 trading days.</p>\n<p>Advancing issues outnumbered declining ones on the NYSE by a 2.50-to-1 ratio; on Nasdaq, a 2.49-to-1 ratio favored advancers.</p>\n<p>The S&amp;P 500 posted 31 new 52-week highs and four new lows; the Nasdaq Composite recorded 93 new highs and 80 new lows.</p>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Wall Street ends day with solid gains; investors hail U.S. debt-ceiling truce</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nWall Street ends day with solid gains; investors hail U.S. debt-ceiling truce\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1036604489\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/443ce19704621c837795676028cec868);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Reuters </p>\n<p class=\"h-time\">2021-10-08 06:49</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<ul>\n <li>U.S. Senate rushes to advance $480 bln debt-limit increase</li>\n <li>U.S. weekly jobless claims fall sharply</li>\n <li>Consumer discretionary and materials lead sectors</li>\n <li>Levi Strauss shares soar after profit beat</li>\n <li>Indexes jump: Dow 0.98%, S&amp;P 0.83%, Nasdaq 1.05%</li>\n</ul>\n<p>Oct 7 (Reuters) - Wall Street ended sharply higher on Thursday in a broad-based rally led by Big Tech, as a truce in the debt-ceiling standoff in the U.S. Congress relieved concerns of a possible government debt default this month.</p>\n<p>Mega-cap stocks jumped with Apple Inc&nbsp;up 0.9% and Amazon.com Inc&nbsp;rising 1.2%, the biggest boosts to the S&amp;P 500 and Nasdaq. Tesla&nbsp;and Google-parent Alphabet&nbsp;both rose more than 1%.</p>\n<p>The U.S. Senate took a step toward passing a $480 billion increase in Treasury Department borrowing authority, which would put off another partisan showdown until December.</p>\n<p>Uncertainty over the debt-ceiling negotiations was one concern investors cited in September as the S&amp;P 500 logged its biggest monthly percentage drop since the onset of the coronavirus pandemic in March 2020.</p>\n<p>\"Today's (market) is driven by a slight move in Washington towards rationality about being able to pay their bills, write some checks,\" said Kim Forrest, chief investment officer at Bokeh Capital Partners in Pittsburgh.</p>\n<p>Meanwhile, data showed the number of Americans filing new claims for jobless benefits dropped last week by the most in three months, suggesting the labor market recovery was regaining momentum as the latest wave of COVID-19 infections began to subside.</p>\n<p>The closely watched monthly U.S. jobs report is due on Friday.</p>\n<p>“Today’s numbers reinforce the expectation that employment will take a significant step up in the coming months, and I think that’s positive for the economy,” said Brad Neuman, director of market strategy at Alger.</p>\n<p>\"The market climbed its wall of worry today as fears of a debt-ceiling impasse receded and hopes for an acceleration in employment gains were reinforced.”</p>\n<p>The Dow Jones Industrial Average&nbsp;rose 0.98% to end at 34,754.94 points, while the S&amp;P 500&nbsp;gained 0.83% to 4,399.76.</p>\n<p>The Nasdaq Composite&nbsp;climbed 1.05% to 14,654.02.</p>\n<p>The S&amp;P 500 materials index&nbsp;jumped 1.35% and the consumer discretionary index&nbsp;rallied 1.50%, both leading among 11 sectors.</p>\n<p>U.S.-traded Chinese stocks Alibaba Group Holding&nbsp;and Tencent Holdings&nbsp;each surged about 8% as concerns around U.S.-Sino trade relations and Evergrande's&nbsp;debt crisis appeared to ease.</p>\n<p>Investors will watch third-quarter earnings reports that start to arrive in earnest next week. Analysts on average estimate S&amp;P 500 companies' earnings per share rose 29% in the third quarter, according to Refinitiv.</p>\n<p>Levi Strauss &amp; Co&nbsp;shares jumped 8.5% after the jeans maker beat third-quarter revenue and profit estimates.</p>\n<p>Volume on U.S. exchanges was 10.1 billion shares, compared with the 11 billion average over the last 20 trading days.</p>\n<p>Advancing issues outnumbered declining ones on the NYSE by a 2.50-to-1 ratio; on Nasdaq, a 2.49-to-1 ratio favored advancers.</p>\n<p>The S&amp;P 500 posted 31 new 52-week highs and four new lows; the Nasdaq Composite recorded 93 new highs and 80 new lows.</p>\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"LEVI":"李维斯",".DJI":"道琼斯",".IXIC":"NASDAQ Composite","AAPL":"苹果","AMZN":"亚马逊",".SPX":"S&P 500 Index","TSLA":"特斯拉","TCEHY":"腾讯控股ADR","BABA":"阿里巴巴"},"is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1163018074","content_text":"U.S. Senate rushes to advance $480 bln debt-limit increase\nU.S. weekly jobless claims fall sharply\nConsumer discretionary and materials lead sectors\nLevi Strauss shares soar after profit beat\nIndexes jump: Dow 0.98%, S&P 0.83%, Nasdaq 1.05%\n\nOct 7 (Reuters) - Wall Street ended sharply higher on Thursday in a broad-based rally led by Big Tech, as a truce in the debt-ceiling standoff in the U.S. Congress relieved concerns of a possible government debt default this month.\nMega-cap stocks jumped with Apple Inc up 0.9% and Amazon.com Inc rising 1.2%, the biggest boosts to the S&P 500 and Nasdaq. Tesla and Google-parent Alphabet both rose more than 1%.\nThe U.S. Senate took a step toward passing a $480 billion increase in Treasury Department borrowing authority, which would put off another partisan showdown until December.\nUncertainty over the debt-ceiling negotiations was one concern investors cited in September as the S&P 500 logged its biggest monthly percentage drop since the onset of the coronavirus pandemic in March 2020.\n\"Today's (market) is driven by a slight move in Washington towards rationality about being able to pay their bills, write some checks,\" said Kim Forrest, chief investment officer at Bokeh Capital Partners in Pittsburgh.\nMeanwhile, data showed the number of Americans filing new claims for jobless benefits dropped last week by the most in three months, suggesting the labor market recovery was regaining momentum as the latest wave of COVID-19 infections began to subside.\nThe closely watched monthly U.S. jobs report is due on Friday.\n“Today’s numbers reinforce the expectation that employment will take a significant step up in the coming months, and I think that’s positive for the economy,” said Brad Neuman, director of market strategy at Alger.\n\"The market climbed its wall of worry today as fears of a debt-ceiling impasse receded and hopes for an acceleration in employment gains were reinforced.”\nThe Dow Jones Industrial Average rose 0.98% to end at 34,754.94 points, while the S&P 500 gained 0.83% to 4,399.76.\nThe Nasdaq Composite climbed 1.05% to 14,654.02.\nThe S&P 500 materials index jumped 1.35% and the consumer discretionary index rallied 1.50%, both leading among 11 sectors.\nU.S.-traded Chinese stocks Alibaba Group Holding and Tencent Holdings each surged about 8% as concerns around U.S.-Sino trade relations and Evergrande's debt crisis appeared to ease.\nInvestors will watch third-quarter earnings reports that start to arrive in earnest next week. Analysts on average estimate S&P 500 companies' earnings per share rose 29% in the third quarter, according to Refinitiv.\nLevi Strauss & Co shares jumped 8.5% after the jeans maker beat third-quarter revenue and profit estimates.\nVolume on U.S. exchanges was 10.1 billion shares, compared with the 11 billion average over the last 20 trading days.\nAdvancing issues outnumbered declining ones on the NYSE by a 2.50-to-1 ratio; on Nasdaq, a 2.49-to-1 ratio favored advancers.\nThe S&P 500 posted 31 new 52-week highs and four new lows; the Nasdaq Composite recorded 93 new highs and 80 new lows.","news_type":1},"isVote":1,"tweetType":1,"viewCount":669,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0}],"hots":[{"id":822982110,"gmtCreate":1634085093240,"gmtModify":1634085093353,"author":{"id":"4095759201622640","authorId":"4095759201622640","name":"prettysongbk","avatar":"https://static.tigerbbs.com/88ac06c4861b9c5d61510736f27ebfb6","crmLevel":2,"crmLevelSwitch":0,"followedFlag":false,"authorIdStr":"4095759201622640","idStr":"4095759201622640"},"themes":[],"htmlText":"[Surprised]&nbsp;","listText":"[Surprised]&nbsp;","text":"[Surprised]","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":8,"commentSize":1,"repostSize":0,"link":"https://laohu8.com/post/822982110","repostId":"2175132100","repostType":4,"repost":{"id":"2175132100","weMediaInfo":{"introduction":"Reuters.com brings you the latest news from around the world, covering breaking news in markets, business, politics, entertainment and technology","home_visible":1,"media_name":"Reuters","id":"1036604489","head_image":"https://static.tigerbbs.com/443ce19704621c837795676028cec868"},"pubTimestamp":1634079953,"share":"https://www.laohu8.com/m/news/2175132100?lang=&edition=full","pubTime":"2021-10-13 07:05","market":"us","language":"en","title":"Wall Street closes lower on jitters ahead of earnings, Fed minutes","url":"https://stock-news.laohu8.com/highlight/detail?id=2175132100","media":"Reuters","summary":"NEW YORK, Oct 12 (Reuters) - U.S. stocks finished lower on Tuesday, extending losses late as investo","content":"<p>NEW YORK, Oct 12 (Reuters) - U.S. stocks finished lower on Tuesday, extending losses late as investors grew more jittery in the run up to third-quarter earnings, while a jump in Tesla shares helped support the market.</p>\n<p>Adding to investor caution, the Federal Reserve is expected to release minutes on Wednesday from its last policy meeting, which market participants will scour for hints about when the U.S. central bank could begin tapering its massive bond-buying program.</p>\n<p>All three major U.S. stock indexes ended in the red with the Dow down the most, weighed by healthcare&nbsp;and industrials .</p>\n<p>Earnings unofficially kick off this week with results from JPMorgan Chase &amp; Co&nbsp;on Wednesday and other banks to follow. JPMorgan's shares shed 0.8% on the day, while the S&amp;P 500 banks index&nbsp;edged down 0.6%.</p>\n<p>Analysts expect to see strong U.S. profit growth for the third quarter. But a number of companies have warned of issues and investors are worried about how supply chain problems and higher prices will affect businesses emerging from the coronavirus pandemic.</p>\n<p>\"For the most part, institutional portfolio managers are of the view - let's see what earnings look like and how much of a negative impact is being seen from shortages, higher rates and supply chain bottlenecks,\" said Michael James, managing director of equity trading at Wedbush Securities in Los Angeles.</p>\n<p>\"A lot of those factors are currently reflected where equity prices are now.\"</p>\n<p>The Dow Jones Industrial Average&nbsp;fell 117.72 points, or 0.34%, to 34,378.34, the S&amp;P 500&nbsp;lost 10.54 points, or 0.24%, to 4,350.65 and the Nasdaq Composite&nbsp;dropped 20.28 points, or 0.14%, to 14,465.93.</p>\n<p>Six of the 11 major sectors of the S&amp;P 500 ended the session in the red, with communications services&nbsp;suffering the steepest percentage loss.</p>\n<p>Tesla&nbsp;advanced 1.7% after data showed the electric vehicle maker sold 56,006 China-made vehicles in September, the highest since it started production in Shanghai about two years ago. The company's shares provided the biggest boost to the S&amp;P 500 and the Nasdaq.</p>\n<p>Shares of American Airlines Group&nbsp;rose 0.8% after the company estimated a smaller-than-expected adjusted loss for the third quarter and signaled improved bookings for the rest of the year.</p>\n<p>MGM Resorts&nbsp;surged 9.6% after of Credit Suisse upgraded the stock to \"outperform\" from \"neutral.\"</p>\n<p>Nike Inc&nbsp;gained 2.0% after Goldman Sachs initiated coverage with a \"buy\" recommendation.</p>\n<p>Investors also weighed comments from Fed Vice Chair Richard Clarida, who said the central bank has all but met its employment goal for reducing its bond buying program.</p>\n<p>U.S. data showed the labor market remained tight, with a record number of Americans quitting their jobs and job vacancies numbering more than 10 million, stoking inflation fears as employers hike wages to attract and retain workers.</p>\n<p>Wednesday's consumer price index report will attract attention from investors seeking clues about inflation.</p>\n<p>Advancing issues outnumbered declining ones on the NYSE by a 1.38-to-1 ratio; on Nasdaq, a 1.42-to-1 ratio favored advancers.</p>\n<p>The S&amp;P 500 posted 10 new 52-week highs and 10 new lows; the Nasdaq Composite recorded 46 new highs and 94 new lows.</p>\n<p>Volume on U.S. exchanges was 9.17 billion shares, compared with the 10.80 billion average over the last 20 trading days.</p>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Wall Street closes lower on jitters ahead of earnings, Fed minutes</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nWall Street closes lower on jitters ahead of earnings, Fed minutes\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1036604489\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/443ce19704621c837795676028cec868);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Reuters </p>\n<p class=\"h-time\">2021-10-13 07:05</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>NEW YORK, Oct 12 (Reuters) - U.S. stocks finished lower on Tuesday, extending losses late as investors grew more jittery in the run up to third-quarter earnings, while a jump in Tesla shares helped support the market.</p>\n<p>Adding to investor caution, the Federal Reserve is expected to release minutes on Wednesday from its last policy meeting, which market participants will scour for hints about when the U.S. central bank could begin tapering its massive bond-buying program.</p>\n<p>All three major U.S. stock indexes ended in the red with the Dow down the most, weighed by healthcare&nbsp;and industrials .</p>\n<p>Earnings unofficially kick off this week with results from JPMorgan Chase &amp; Co&nbsp;on Wednesday and other banks to follow. JPMorgan's shares shed 0.8% on the day, while the S&amp;P 500 banks index&nbsp;edged down 0.6%.</p>\n<p>Analysts expect to see strong U.S. profit growth for the third quarter. But a number of companies have warned of issues and investors are worried about how supply chain problems and higher prices will affect businesses emerging from the coronavirus pandemic.</p>\n<p>\"For the most part, institutional portfolio managers are of the view - let's see what earnings look like and how much of a negative impact is being seen from shortages, higher rates and supply chain bottlenecks,\" said Michael James, managing director of equity trading at Wedbush Securities in Los Angeles.</p>\n<p>\"A lot of those factors are currently reflected where equity prices are now.\"</p>\n<p>The Dow Jones Industrial Average&nbsp;fell 117.72 points, or 0.34%, to 34,378.34, the S&amp;P 500&nbsp;lost 10.54 points, or 0.24%, to 4,350.65 and the Nasdaq Composite&nbsp;dropped 20.28 points, or 0.14%, to 14,465.93.</p>\n<p>Six of the 11 major sectors of the S&amp;P 500 ended the session in the red, with communications services&nbsp;suffering the steepest percentage loss.</p>\n<p>Tesla&nbsp;advanced 1.7% after data showed the electric vehicle maker sold 56,006 China-made vehicles in September, the highest since it started production in Shanghai about two years ago. The company's shares provided the biggest boost to the S&amp;P 500 and the Nasdaq.</p>\n<p>Shares of American Airlines Group&nbsp;rose 0.8% after the company estimated a smaller-than-expected adjusted loss for the third quarter and signaled improved bookings for the rest of the year.</p>\n<p>MGM Resorts&nbsp;surged 9.6% after of Credit Suisse upgraded the stock to \"outperform\" from \"neutral.\"</p>\n<p>Nike Inc&nbsp;gained 2.0% after Goldman Sachs initiated coverage with a \"buy\" recommendation.</p>\n<p>Investors also weighed comments from Fed Vice Chair Richard Clarida, who said the central bank has all but met its employment goal for reducing its bond buying program.</p>\n<p>U.S. data showed the labor market remained tight, with a record number of Americans quitting their jobs and job vacancies numbering more than 10 million, stoking inflation fears as employers hike wages to attract and retain workers.</p>\n<p>Wednesday's consumer price index report will attract attention from investors seeking clues about inflation.</p>\n<p>Advancing issues outnumbered declining ones on the NYSE by a 1.38-to-1 ratio; on Nasdaq, a 1.42-to-1 ratio favored advancers.</p>\n<p>The S&amp;P 500 posted 10 new 52-week highs and 10 new lows; the Nasdaq Composite recorded 46 new highs and 94 new lows.</p>\n<p>Volume on U.S. exchanges was 9.17 billion shares, compared with the 10.80 billion average over the last 20 trading days.</p>\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{},"is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"2175132100","content_text":"NEW YORK, Oct 12 (Reuters) - U.S. stocks finished lower on Tuesday, extending losses late as investors grew more jittery in the run up to third-quarter earnings, while a jump in Tesla shares helped support the market.\nAdding to investor caution, the Federal Reserve is expected to release minutes on Wednesday from its last policy meeting, which market participants will scour for hints about when the U.S. central bank could begin tapering its massive bond-buying program.\nAll three major U.S. stock indexes ended in the red with the Dow down the most, weighed by healthcare and industrials .\nEarnings unofficially kick off this week with results from JPMorgan Chase & Co on Wednesday and other banks to follow. JPMorgan's shares shed 0.8% on the day, while the S&P 500 banks index edged down 0.6%.\nAnalysts expect to see strong U.S. profit growth for the third quarter. But a number of companies have warned of issues and investors are worried about how supply chain problems and higher prices will affect businesses emerging from the coronavirus pandemic.\n\"For the most part, institutional portfolio managers are of the view - let's see what earnings look like and how much of a negative impact is being seen from shortages, higher rates and supply chain bottlenecks,\" said Michael James, managing director of equity trading at Wedbush Securities in Los Angeles.\n\"A lot of those factors are currently reflected where equity prices are now.\"\nThe Dow Jones Industrial Average fell 117.72 points, or 0.34%, to 34,378.34, the S&P 500 lost 10.54 points, or 0.24%, to 4,350.65 and the Nasdaq Composite dropped 20.28 points, or 0.14%, to 14,465.93.\nSix of the 11 major sectors of the S&P 500 ended the session in the red, with communications services suffering the steepest percentage loss.\nTesla advanced 1.7% after data showed the electric vehicle maker sold 56,006 China-made vehicles in September, the highest since it started production in Shanghai about two years ago. The company's shares provided the biggest boost to the S&P 500 and the Nasdaq.\nShares of American Airlines Group rose 0.8% after the company estimated a smaller-than-expected adjusted loss for the third quarter and signaled improved bookings for the rest of the year.\nMGM Resorts surged 9.6% after of Credit Suisse upgraded the stock to \"outperform\" from \"neutral.\"\nNike Inc gained 2.0% after Goldman Sachs initiated coverage with a \"buy\" recommendation.\nInvestors also weighed comments from Fed Vice Chair Richard Clarida, who said the central bank has all but met its employment goal for reducing its bond buying program.\nU.S. data showed the labor market remained tight, with a record number of Americans quitting their jobs and job vacancies numbering more than 10 million, stoking inflation fears as employers hike wages to attract and retain workers.\nWednesday's consumer price index report will attract attention from investors seeking clues about inflation.\nAdvancing issues outnumbered declining ones on the NYSE by a 1.38-to-1 ratio; on Nasdaq, a 1.42-to-1 ratio favored advancers.\nThe S&P 500 posted 10 new 52-week highs and 10 new lows; the Nasdaq Composite recorded 46 new highs and 94 new lows.\nVolume on U.S. exchanges was 9.17 billion shares, compared with the 10.80 billion average over the last 20 trading days.","news_type":1},"isVote":1,"tweetType":1,"viewCount":599,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},{"id":600868884,"gmtCreate":1638139033252,"gmtModify":1638139033252,"author":{"id":"4095759201622640","authorId":"4095759201622640","name":"prettysongbk","avatar":"https://static.tigerbbs.com/88ac06c4861b9c5d61510736f27ebfb6","crmLevel":2,"crmLevelSwitch":0,"followedFlag":false,"authorIdStr":"4095759201622640","idStr":"4095759201622640"},"themes":[],"htmlText":"I love Lulu&nbsp;","listText":"I love Lulu&nbsp;","text":"I love Lulu","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":7,"commentSize":1,"repostSize":0,"link":"https://laohu8.com/post/600868884","repostId":"1117671420","repostType":4,"repost":{"id":"1117671420","pubTimestamp":1638067569,"share":"https://www.laohu8.com/m/news/1117671420?lang=&edition=full","pubTime":"2021-11-28 10:46","market":"us","language":"en","title":"Lululemon Earnings: What to Watch on Dec. 9","url":"https://stock-news.laohu8.com/highlight/detail?id=1117671420","media":"Motley Fool","summary":"$Lululemon Athletica $ is slated to report its results for the third quarter of fiscal 2021  after the market close on Thursday, Dec. 9.Investors in the athletic apparel retailer are probably feeling optimistic about the report. Last quarter, revenue and earnings crushed Wall Street's consensus estimates, third-quarter guidance for both the top and bottom lines came in higher than analysts had been expecting, and management significantly hiked its full-year outlook for both revenue and earnings.","content":"<p><a href=\"https://laohu8.com/S/LULU\"><b>Lululemon Athletica</b>&nbsp;</a>&nbsp;is slated to report its results for the third quarter of fiscal 2021 (essentially the August-to-October period) after the market close on Thursday, Dec. 9.</p>\n<p>Investors in the athletic apparel retailer are probably feeling optimistic about the report. Last quarter, revenue and earnings crushed Wall Street's consensus estimates, third-quarter guidance for both the top and bottom lines came in higher than analysts had been expecting, and management significantly hiked its full-year outlook for both revenue and earnings. Moreover, many investors are enthused about the company's potential to be a major player in the growing home connected-fitness market, thanks to its acquisition of Mirror last year.</p>\n<p>In 2021, Lululemon stock is outrunning the market. Through Nov. 26, it's up 31.3% versus the&nbsp;<b>S&amp;P 500</b>'s 23.9% return.</p>\n<p>Here's what to watch in Lululemon's upcoming report.</p>\n<p><img src=\"https://static.tigerbbs.com/004c779d4dc4a363ecab86afd4b9cd2c\" tg-width=\"1053\" tg-height=\"339\" width=\"100%\" height=\"auto\">Investors can probably expect that the company's sales and earnings were hurt to some degree by the pandemic-driven global supply chain issues that are afflictingretailersand many other types of companies. That said, Lululemon's management has been doing a good job limiting the impact of this headwind.</p>\n<p>For context,last quarter(essentially the May-to-July period), Lululemon's sales soared 61% year over year to $1.45 billion, sprinting by the 47% growth Wall Street had expected. Growth was driven by a 142% surge in company-operated stores' revenue to $695.1 million, as many consumers returned to shopping in brick-and-mortar stores. Direct-to-consumer sales rose 8% to $597.4 million. Adjusted EPS skyrocketed 123% to $1.65, leaving the analyst consensus estimate of $1.19 in the dust.</p>\n<p>Last quarter's results were particularly strong because of the easy year-ago comparable. The year-ago period occurred early in the pandemic when consumers were cutting back their spending on non-essential products.</p>\n<p>Mirror</p>\n<p>Management hasn't been providing sales data for Mirror, \"a nearly invisible interactive home gym,\" to use Lululemon's words. But investors can expect an update on the earnings call about the company's relatively new home connected-fitness business.</p>\n<p>On last quarter's earnings call in early September, CEO Calvin McDonald said the company had Mirror shop-in-shops in 150 Lululemon stores with plans to increase that number to 200 by the holiday season. He added that the company would soon introduce Mirror to the Canadian market. Indeed, in early October, Lululemon announced that Mirror would be available in 40 of its stores across Canada and available for online purchase in the country beginning on Nov. 22.</p>\n<p>Guidance for the holiday quarter</p>\n<p>As always, Lululemon's guidance, relative to Wall Street's expectations, should be a major factor in the market's reaction to its upcoming report. Investors will likely be putting significant weight on the quarterly outlook because the holiday period is particularly important to retailers. For fiscal Q4 (essentially the November-to-January period), Wall Street is modeling for revenue to jump 28% year over year to $2.21 billion and adjusted EPS to also increase 28%, to $3.30.</p>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Lululemon Earnings: What to Watch on Dec. 9</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nLululemon Earnings: What to Watch on Dec. 9\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-11-28 10:46 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.fool.com/investing/2021/11/27/lululemon-earnings-what-to-watch-on-dec-9/><strong>Motley Fool</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Lululemon Athletica  is slated to report its results for the third quarter of fiscal 2021 (essentially the August-to-October period) after the market close on Thursday, Dec. 9.\nInvestors in the ...</p>\n\n<a href=\"https://www.fool.com/investing/2021/11/27/lululemon-earnings-what-to-watch-on-dec-9/\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"LULU":"lululemon athletica"},"source_url":"https://www.fool.com/investing/2021/11/27/lululemon-earnings-what-to-watch-on-dec-9/","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1117671420","content_text":"Lululemon Athletica  is slated to report its results for the third quarter of fiscal 2021 (essentially the August-to-October period) after the market close on Thursday, Dec. 9.\nInvestors in the athletic apparel retailer are probably feeling optimistic about the report. Last quarter, revenue and earnings crushed Wall Street's consensus estimates, third-quarter guidance for both the top and bottom lines came in higher than analysts had been expecting, and management significantly hiked its full-year outlook for both revenue and earnings. Moreover, many investors are enthused about the company's potential to be a major player in the growing home connected-fitness market, thanks to its acquisition of Mirror last year.\nIn 2021, Lululemon stock is outrunning the market. Through Nov. 26, it's up 31.3% versus the S&P 500's 23.9% return.\nHere's what to watch in Lululemon's upcoming report.\nInvestors can probably expect that the company's sales and earnings were hurt to some degree by the pandemic-driven global supply chain issues that are afflictingretailersand many other types of companies. That said, Lululemon's management has been doing a good job limiting the impact of this headwind.\nFor context,last quarter(essentially the May-to-July period), Lululemon's sales soared 61% year over year to $1.45 billion, sprinting by the 47% growth Wall Street had expected. Growth was driven by a 142% surge in company-operated stores' revenue to $695.1 million, as many consumers returned to shopping in brick-and-mortar stores. Direct-to-consumer sales rose 8% to $597.4 million. Adjusted EPS skyrocketed 123% to $1.65, leaving the analyst consensus estimate of $1.19 in the dust.\nLast quarter's results were particularly strong because of the easy year-ago comparable. The year-ago period occurred early in the pandemic when consumers were cutting back their spending on non-essential products.\nMirror\nManagement hasn't been providing sales data for Mirror, \"a nearly invisible interactive home gym,\" to use Lululemon's words. But investors can expect an update on the earnings call about the company's relatively new home connected-fitness business.\nOn last quarter's earnings call in early September, CEO Calvin McDonald said the company had Mirror shop-in-shops in 150 Lululemon stores with plans to increase that number to 200 by the holiday season. He added that the company would soon introduce Mirror to the Canadian market. Indeed, in early October, Lululemon announced that Mirror would be available in 40 of its stores across Canada and available for online purchase in the country beginning on Nov. 22.\nGuidance for the holiday quarter\nAs always, Lululemon's guidance, relative to Wall Street's expectations, should be a major factor in the market's reaction to its upcoming report. Investors will likely be putting significant weight on the quarterly outlook because the holiday period is particularly important to retailers. For fiscal Q4 (essentially the November-to-January period), Wall Street is modeling for revenue to jump 28% year over year to $2.21 billion and adjusted EPS to also increase 28%, to $3.30.","news_type":1},"isVote":1,"tweetType":1,"viewCount":651,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},{"id":871443313,"gmtCreate":1637108445809,"gmtModify":1637108445938,"author":{"id":"4095759201622640","authorId":"4095759201622640","name":"prettysongbk","avatar":"https://static.tigerbbs.com/88ac06c4861b9c5d61510736f27ebfb6","crmLevel":2,"crmLevelSwitch":0,"followedFlag":false,"authorIdStr":"4095759201622640","idStr":"4095759201622640"},"themes":[],"htmlText":"Wowwwww","listText":"Wowwwww","text":"Wowwwww","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":5,"commentSize":1,"repostSize":0,"link":"https://laohu8.com/post/871443313","repostId":"2184847528","repostType":4,"repost":{"id":"2184847528","pubTimestamp":1637108100,"share":"https://www.laohu8.com/m/news/2184847528?lang=&edition=full","pubTime":"2021-11-17 08:15","market":"us","language":"en","title":"A new Big Three? Rivian and Lucid's valuations are accelerating past Ford, GM","url":"https://stock-news.laohu8.com/highlight/detail?id=2184847528","media":"MarketWatch","summary":"Rivian, Lucid pass Ford as the hunt for the next Tesla continues\nRivian stock is up 61% since its fi","content":"<p>Rivian, Lucid pass Ford as the hunt for the next Tesla continues</p>\n<p class=\"t-img-caption\"><img src=\"https://static.tigerbbs.com/b65c1d2713c7d614783579796548161c\" tg-width=\"700\" tg-height=\"466\" width=\"100%\" height=\"auto\"><span>Rivian stock is up 61% since its first trade last week. Getty Images</span></p>\n<p>Rivian Automotive Inc.'s market valuation is already nearly double that of Ford Motor Co. and zoomed past General Motors Co. a week into the electric-vehicle startup's life as a public company, while rival Lucid Motors' market value closed in on GM's and topped Ford's on Tuesday, underscoring investors' appetite for EV makers and the hunt for the next Tesla Inc.</p>\n<p>Rivian went public last Tuesday after the biggest initial public offering of the year and seventh-largest U.S. IPO since the mid-1990s. The stock ended 15% higher on Tuesday, boosting the company's valuation a little over $148 billion.</p>\n<p>That compares to Ford's&nbsp;valuation around $78 billion and GM's&nbsp;at about $91 billion on Tuesday. Tesla&nbsp;is the highest-valued auto maker in the U.S., at a market capitalization above $1 trillion.</p>\n<p>Rivian stock has gained 61% since its first trade of $106.75 last week, and 121% from its IPO price of $78.</p>\n<p>Lucid shares&nbsp;jumped 24% to close at $55.52 on Tuesday, pushing the EV maker's valuation to slightly under $89 billion. That was the stock's highest close since Feb. 22, when it closed at $57.37.</p>\n<p>Lucid, which has been hailed as the \"Tesla/Ferrari\" of EVs and focuses on the high-end market, went public through a blank-check company deal and the stock started trading on the Nasdaq in July. The EV maker said Monday its orders rose 30%, with \"significant\" demand for its Lucid Air luxury EV.</p>\n<p>Rivian already has delivered a few limited-edition R1Ts, its two-row, five-seat pickup truck, and plans to launch an SUV, the R1S, in December. Volume sales of the pickup and the SUV are expected to begin in December and January.</p>\n<p>Rivian markets its vehicles as \"electric adventure vehicles\" with prices starting at the low $70,000s, which has led some to question the size of its market, with cheaper electric pickups, including Ford's Lightning F-150, slated for next year.</p>\n<p>The Ford Lightning is expected to start at about $40,000, and the cachet of being the electric version of the U.S. best-selling vehicle for decades comes free of charge. GM plans to unveil an electric Silverado next year as well.</p>","source":"lsy1603348471595","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>A new Big Three? Rivian and Lucid's valuations are accelerating past Ford, GM</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nA new Big Three? Rivian and Lucid's valuations are accelerating past Ford, GM\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-11-17 08:15 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.marketwatch.com/story/a-new-big-three-rivian-and-lucids-valuations-are-accelerating-past-ford-gm-11637102012?mod=home-page><strong>MarketWatch</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Rivian, Lucid pass Ford as the hunt for the next Tesla continues\nRivian stock is up 61% since its first trade last week. Getty Images\nRivian Automotive Inc.'s market valuation is already nearly double...</p>\n\n<a href=\"https://www.marketwatch.com/story/a-new-big-three-rivian-and-lucids-valuations-are-accelerating-past-ford-gm-11637102012?mod=home-page\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{},"source_url":"https://www.marketwatch.com/story/a-new-big-three-rivian-and-lucids-valuations-are-accelerating-past-ford-gm-11637102012?mod=home-page","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"2184847528","content_text":"Rivian, Lucid pass Ford as the hunt for the next Tesla continues\nRivian stock is up 61% since its first trade last week. Getty Images\nRivian Automotive Inc.'s market valuation is already nearly double that of Ford Motor Co. and zoomed past General Motors Co. a week into the electric-vehicle startup's life as a public company, while rival Lucid Motors' market value closed in on GM's and topped Ford's on Tuesday, underscoring investors' appetite for EV makers and the hunt for the next Tesla Inc.\nRivian went public last Tuesday after the biggest initial public offering of the year and seventh-largest U.S. IPO since the mid-1990s. The stock ended 15% higher on Tuesday, boosting the company's valuation a little over $148 billion.\nThat compares to Ford's valuation around $78 billion and GM's at about $91 billion on Tuesday. Tesla is the highest-valued auto maker in the U.S., at a market capitalization above $1 trillion.\nRivian stock has gained 61% since its first trade of $106.75 last week, and 121% from its IPO price of $78.\nLucid shares jumped 24% to close at $55.52 on Tuesday, pushing the EV maker's valuation to slightly under $89 billion. That was the stock's highest close since Feb. 22, when it closed at $57.37.\nLucid, which has been hailed as the \"Tesla/Ferrari\" of EVs and focuses on the high-end market, went public through a blank-check company deal and the stock started trading on the Nasdaq in July. The EV maker said Monday its orders rose 30%, with \"significant\" demand for its Lucid Air luxury EV.\nRivian already has delivered a few limited-edition R1Ts, its two-row, five-seat pickup truck, and plans to launch an SUV, the R1S, in December. Volume sales of the pickup and the SUV are expected to begin in December and January.\nRivian markets its vehicles as \"electric adventure vehicles\" with prices starting at the low $70,000s, which has led some to question the size of its market, with cheaper electric pickups, including Ford's Lightning F-150, slated for next year.\nThe Ford Lightning is expected to start at about $40,000, and the cachet of being the electric version of the U.S. best-selling vehicle for decades comes free of charge. GM plans to unveil an electric Silverado next year as well.","news_type":1},"isVote":1,"tweetType":1,"viewCount":551,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},{"id":873393299,"gmtCreate":1636854438424,"gmtModify":1636854438424,"author":{"id":"4095759201622640","authorId":"4095759201622640","name":"prettysongbk","avatar":"https://static.tigerbbs.com/88ac06c4861b9c5d61510736f27ebfb6","crmLevel":2,"crmLevelSwitch":0,"followedFlag":false,"authorIdStr":"4095759201622640","idStr":"4095759201622640"},"themes":[],"htmlText":"Ok","listText":"Ok","text":"Ok","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":4,"commentSize":1,"repostSize":0,"link":"https://laohu8.com/post/873393299","repostId":"1102251183","repostType":4,"repost":{"id":"1102251183","pubTimestamp":1636772424,"share":"https://www.laohu8.com/m/news/1102251183?lang=&edition=full","pubTime":"2021-11-13 11:00","market":"us","language":"en","title":"Pfizer Shows Its R&D Is Strong. It’s a Good Sign for the Stock.","url":"https://stock-news.laohu8.com/highlight/detail?id=1102251183","media":"Barrons","summary":"Pfizer’s chief scientific officer, Mikael Dolsten, sounded giddy when reached via telephone early Mo","content":"<p>Pfizer’s&nbsp;chief scientific officer, Mikael Dolsten, sounded giddy when reached via telephone early Monday morning. It was just days after his company knocked the socks off the market with the news that its Covid-19 antiviral had cut the risk of hospitalization by 89% in high-risk adults.</p>\n<p>“It can’t be just a random thing, that you’re able to beat this type of world record and get a grand slam at the same time by chance,” Dolsten said, scrambling sports metaphors as he sought to illustrate the magnitude of Pfizer’s twin wins: the development of a stunningly effective Covid-19 vaccine in just 10 months, followed a year later by the development of a similarly stunning Covid-19 antiviral.</p>\n<p>Two years ago, Pfizer (ticker: PFE) CEO Albert Bourla asked investors to take a big gamble on the research-and-development operation that Dolsten has rebuilt over the course of more than a decade. That bet is looking smarter than ever.</p>\n<p>Bourla has gotten rid of Pfizer’s off-patent drugs division and the last of its consumer health products, leaving behind a pure-play biopharma company that will live or die on the strength of Dolsten’s science.</p>\n<p>In a cover story in November 2019, <i>Barron’s</i> argued that Bourla and Dolsten could pull it off.</p>\n<p>The new antiviral data reaffirms the case for Pfizer that <i>Barron’s</i> made two years ago. Continuing to profit off the pandemic, however, brings new risks, as criticism grows over the global inequity in vaccine distribution. Low-income nations account for less than 1% of the more than seven billion doses administered worldwide. If distribution of Pfizer’s antiviral continues to favor wealthy nations, the company’s stock could ultimately suffer.</p>\n<p>Pfizer’s shares surged 10.9% the day the data came out, their best daily showing in at least 20 years. Still, with the stock now changing hands at around $50, investors continue to undervalue the company. Investors are pricing Pfizer at 12 times next year’s expected earnings, cheaper than peers like&nbsp;Johnson &amp; Johnson&nbsp;(JNJ) and&nbsp;Eli Lilly&nbsp;(LLY).</p>\n<p>The Pfizer discount can be attributed to concerns over the patent cliff the drugmaker faces at the end of the decade. The company stands to lose exclusivity over a handful of drugs that bring in billions in annual revenue.</p>\n<p>The worries are legitimate, but Pfizer’s scientific coup should give investors confidence that the company’s science can carry it safely over that cliff. It may take time for the market to catch up, but for long-term investors, it’s a promising opportunity.</p>\n<p>The success of the antiviral is the best illustration yet of Pfizer’s scientific prowess.</p>\n<p>While Pfizer’s Covid-19 vaccine came out of the labs of the German biotech&nbsp;BioNTech&nbsp;(BNTX), the new Covid-19 antiviral was whipped up by what Dolsten called a “dream team” of scientists at Pfizer’s own labs across the Northeast U.S.</p>\n<p>In the earliest days of the pandemic, Pfizer split its efforts between its collaboration with BioNTech on the vaccine and its quest for a Covid-19 pill. The vaccine effort operated on a huge scale; Dolsten called it a “mega team” that spanned the Atlantic.</p>\n<p>The antiviral project was a much smaller operation—a group of Pfizer experts operating with resources left over from the vaccine push.</p>\n<p>“The small molecule was more like a nimble, laser-focused, high-end team, with rather moderate resources,” Dolsten said.</p>\n<p>Dolsten gathered some of Pfizer’s most experienced scientists to work on the antiviral project, including its head of medicine design, Charlotte Allerton. The scientists started with work Pfizer had done years ago on a type of antiviral called a protease inhibitor.</p>\n<p>“[Pfizer’s] pharmaceutical R&amp;D is better than people had thought.”</p>\n<p>The protease inhibitors in the Pfizer library, however, had been administered intravenously, and had not worked well when delivered orally. The team had to figure out how to adapt the drugs to oral administration, a substantial undertaking.</p>\n<p>“They had to really create a lot of new chemistry,” Dolsten said. The scientists created 600 compounds to nail down the right drug, a process that might normally take years, and which they accomplished in a matter of months. “Four years turned into four months here,” he said.</p>\n<p>Pfizer started testing the pill in humans in March. It is now running a number of Phase 2/3 trials of the drug, including one for patients who are high risk, one for patients not high risk, and one as a prophylaxis for patients who have been exposed to the virus but aren’t yet sick. In the first readout, the drug looked substantially more effective than the Covid treatment pill from&nbsp;Merck&nbsp;(MRK).</p>\n<p>“It definitely helps prove the point that [Pfizer’s] pharmaceutical R&amp;D is better than people had thought,” says Louise Chen, an analyst at Cantor Fitzgerald, who has an Overweight rating and a $61 price target on the stock.</p>\n<p>Chen says that she doesn’t expect investors to come around to her way of thinking until there is more clarity on the durability of Covid-19 vaccine and pill sales, and the rest of the pipeline gets proved out.</p>\n<p>“There is not one event that I think will trigger a re-rating of the stock at the next level,” she says. “Until those things play out, I don’t think that it necessarily will.”</p>\n<p>That makes a bet on Pfizer a long-term play. In the meantime, the experience of&nbsp;Moderna&nbsp;(MRNA) in recent weeks is highlighting the potential for the vaccine makers to come under scrutiny over unequal distribution of vaccines.</p>\n<p>Biden administration officials have been increasingly frustrated with Moderna, calling on the company to ramp up production so it can offer more doses at not-for-profit prices to low-income countries, with one top official calling on the company to “step up.”</p>\n<p>Moderna shares are down more than 40% over the past three months.</p>\n<p>As the pandemic persists, Pfizer risks eroding the enormous goodwill it earned roughly a year ago when it introduced its Covid-19 vaccine. Earlier this month, Pfizer CEO Bourla blamed low-income countries for unfair vaccine distribution, telling <i>Barron’s</i> that it was their fault for not placing orders. Pfizer has sold a billion vaccine doses to the U.S. at a not-for-profit price to donate to poor countries, and says that a total of at least two billion doses will be delivered to low- and middle-income nations by the end of next year.</p>\n<p>When it comes to antivirals, Pfizer has said only that it will offer tiered pricing for poorer nations, the same approach it has taken with its vaccine.</p>\n<p>That contrasts sharply with Merck’s plan to make its own Covid-19 pill available to poor countries. Merck has signed a deal with a United Nations-backed group that will allow its pill to be licensed globally, with no royalties paid to Merck.</p>\n<p>Dolsten said that Pfizer is looking into licensing its pill under a similar mechanism as Merck’s. “We will look at those options,” he said. “By no means have we said we would do something different. We just want to make sure whoever will be involved gets the advice and skill to do this.”</p>\n<p>Such a step couldn’t come soon enough. Late last month, activists protested outside Bourla’s home, calling on Pfizer to share its vaccine manufacturing technology and to fill orders from low-income countries ahead of those from wealthy countries.</p>\n<p>An aggressive plan to share its antiviral would help stave off such criticism, keeping Pfizer in the relative good graces of Washington and allowing its impressive science to continue to drive the stock higher.</p>","source":"lsy1601382232898","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Pfizer Shows Its R&D Is Strong. It’s a Good Sign for the Stock.</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nPfizer Shows Its R&D Is Strong. It’s a Good Sign for the Stock.\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-11-13 11:00 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.barrons.com/articles/buy-pfizer-stock-covid-19-51636674652?mod=hp_LEAD_1><strong>Barrons</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Pfizer’s chief scientific officer, Mikael Dolsten, sounded giddy when reached via telephone early Monday morning. It was just days after his company knocked the socks off the market with the news that...</p>\n\n<a href=\"https://www.barrons.com/articles/buy-pfizer-stock-covid-19-51636674652?mod=hp_LEAD_1\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{},"source_url":"https://www.barrons.com/articles/buy-pfizer-stock-covid-19-51636674652?mod=hp_LEAD_1","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1102251183","content_text":"Pfizer’s chief scientific officer, Mikael Dolsten, sounded giddy when reached via telephone early Monday morning. It was just days after his company knocked the socks off the market with the news that its Covid-19 antiviral had cut the risk of hospitalization by 89% in high-risk adults.\n“It can’t be just a random thing, that you’re able to beat this type of world record and get a grand slam at the same time by chance,” Dolsten said, scrambling sports metaphors as he sought to illustrate the magnitude of Pfizer’s twin wins: the development of a stunningly effective Covid-19 vaccine in just 10 months, followed a year later by the development of a similarly stunning Covid-19 antiviral.\nTwo years ago, Pfizer (ticker: PFE) CEO Albert Bourla asked investors to take a big gamble on the research-and-development operation that Dolsten has rebuilt over the course of more than a decade. That bet is looking smarter than ever.\nBourla has gotten rid of Pfizer’s off-patent drugs division and the last of its consumer health products, leaving behind a pure-play biopharma company that will live or die on the strength of Dolsten’s science.\nIn a cover story in November 2019, Barron’s argued that Bourla and Dolsten could pull it off.\nThe new antiviral data reaffirms the case for Pfizer that Barron’s made two years ago. Continuing to profit off the pandemic, however, brings new risks, as criticism grows over the global inequity in vaccine distribution. Low-income nations account for less than 1% of the more than seven billion doses administered worldwide. If distribution of Pfizer’s antiviral continues to favor wealthy nations, the company’s stock could ultimately suffer.\nPfizer’s shares surged 10.9% the day the data came out, their best daily showing in at least 20 years. Still, with the stock now changing hands at around $50, investors continue to undervalue the company. Investors are pricing Pfizer at 12 times next year’s expected earnings, cheaper than peers like Johnson & Johnson (JNJ) and Eli Lilly (LLY).\nThe Pfizer discount can be attributed to concerns over the patent cliff the drugmaker faces at the end of the decade. The company stands to lose exclusivity over a handful of drugs that bring in billions in annual revenue.\nThe worries are legitimate, but Pfizer’s scientific coup should give investors confidence that the company’s science can carry it safely over that cliff. It may take time for the market to catch up, but for long-term investors, it’s a promising opportunity.\nThe success of the antiviral is the best illustration yet of Pfizer’s scientific prowess.\nWhile Pfizer’s Covid-19 vaccine came out of the labs of the German biotech BioNTech (BNTX), the new Covid-19 antiviral was whipped up by what Dolsten called a “dream team” of scientists at Pfizer’s own labs across the Northeast U.S.\nIn the earliest days of the pandemic, Pfizer split its efforts between its collaboration with BioNTech on the vaccine and its quest for a Covid-19 pill. The vaccine effort operated on a huge scale; Dolsten called it a “mega team” that spanned the Atlantic.\nThe antiviral project was a much smaller operation—a group of Pfizer experts operating with resources left over from the vaccine push.\n“The small molecule was more like a nimble, laser-focused, high-end team, with rather moderate resources,” Dolsten said.\nDolsten gathered some of Pfizer’s most experienced scientists to work on the antiviral project, including its head of medicine design, Charlotte Allerton. The scientists started with work Pfizer had done years ago on a type of antiviral called a protease inhibitor.\n“[Pfizer’s] pharmaceutical R&D is better than people had thought.”\nThe protease inhibitors in the Pfizer library, however, had been administered intravenously, and had not worked well when delivered orally. The team had to figure out how to adapt the drugs to oral administration, a substantial undertaking.\n“They had to really create a lot of new chemistry,” Dolsten said. The scientists created 600 compounds to nail down the right drug, a process that might normally take years, and which they accomplished in a matter of months. “Four years turned into four months here,” he said.\nPfizer started testing the pill in humans in March. It is now running a number of Phase 2/3 trials of the drug, including one for patients who are high risk, one for patients not high risk, and one as a prophylaxis for patients who have been exposed to the virus but aren’t yet sick. In the first readout, the drug looked substantially more effective than the Covid treatment pill from Merck (MRK).\n“It definitely helps prove the point that [Pfizer’s] pharmaceutical R&D is better than people had thought,” says Louise Chen, an analyst at Cantor Fitzgerald, who has an Overweight rating and a $61 price target on the stock.\nChen says that she doesn’t expect investors to come around to her way of thinking until there is more clarity on the durability of Covid-19 vaccine and pill sales, and the rest of the pipeline gets proved out.\n“There is not one event that I think will trigger a re-rating of the stock at the next level,” she says. “Until those things play out, I don’t think that it necessarily will.”\nThat makes a bet on Pfizer a long-term play. In the meantime, the experience of Moderna (MRNA) in recent weeks is highlighting the potential for the vaccine makers to come under scrutiny over unequal distribution of vaccines.\nBiden administration officials have been increasingly frustrated with Moderna, calling on the company to ramp up production so it can offer more doses at not-for-profit prices to low-income countries, with one top official calling on the company to “step up.”\nModerna shares are down more than 40% over the past three months.\nAs the pandemic persists, Pfizer risks eroding the enormous goodwill it earned roughly a year ago when it introduced its Covid-19 vaccine. Earlier this month, Pfizer CEO Bourla blamed low-income countries for unfair vaccine distribution, telling Barron’s that it was their fault for not placing orders. Pfizer has sold a billion vaccine doses to the U.S. at a not-for-profit price to donate to poor countries, and says that a total of at least two billion doses will be delivered to low- and middle-income nations by the end of next year.\nWhen it comes to antivirals, Pfizer has said only that it will offer tiered pricing for poorer nations, the same approach it has taken with its vaccine.\nThat contrasts sharply with Merck’s plan to make its own Covid-19 pill available to poor countries. Merck has signed a deal with a United Nations-backed group that will allow its pill to be licensed globally, with no royalties paid to Merck.\nDolsten said that Pfizer is looking into licensing its pill under a similar mechanism as Merck’s. “We will look at those options,” he said. “By no means have we said we would do something different. We just want to make sure whoever will be involved gets the advice and skill to do this.”\nSuch a step couldn’t come soon enough. Late last month, activists protested outside Bourla’s home, calling on Pfizer to share its vaccine manufacturing technology and to fill orders from low-income countries ahead of those from wealthy countries.\nAn aggressive plan to share its antiviral would help stave off such criticism, keeping Pfizer in the relative good graces of Washington and allowing its impressive science to continue to drive the stock higher.","news_type":1},"isVote":1,"tweetType":1,"viewCount":593,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},{"id":823566029,"gmtCreate":1633649918275,"gmtModify":1633649918367,"author":{"id":"4095759201622640","authorId":"4095759201622640","name":"prettysongbk","avatar":"https://static.tigerbbs.com/88ac06c4861b9c5d61510736f27ebfb6","crmLevel":2,"crmLevelSwitch":0,"followedFlag":false,"authorIdStr":"4095759201622640","idStr":"4095759201622640"},"themes":[],"htmlText":"[Happy]&nbsp;[Miser]&nbsp;$$$$","listText":"[Happy]&nbsp;[Miser]&nbsp;$$$$","text":"[Happy] [Miser] $$$$","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":5,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/823566029","repostId":"1163018074","repostType":4,"repost":{"id":"1163018074","weMediaInfo":{"introduction":"Reuters.com brings you the latest news from around the world, covering breaking news in markets, business, politics, entertainment and technology","home_visible":1,"media_name":"Reuters","id":"1036604489","head_image":"https://static.tigerbbs.com/443ce19704621c837795676028cec868"},"pubTimestamp":1633646971,"share":"https://www.laohu8.com/m/news/1163018074?lang=&edition=full","pubTime":"2021-10-08 06:49","market":"us","language":"en","title":"Wall Street ends day with solid gains; investors hail U.S. debt-ceiling truce","url":"https://stock-news.laohu8.com/highlight/detail?id=1163018074","media":"Reuters","summary":"U.S. Senate rushes to advance $480 bln debt-limit increase\nU.S. weekly jobless claims fall sharply\nC","content":"<ul>\n <li>U.S. Senate rushes to advance $480 bln debt-limit increase</li>\n <li>U.S. weekly jobless claims fall sharply</li>\n <li>Consumer discretionary and materials lead sectors</li>\n <li>Levi Strauss shares soar after profit beat</li>\n <li>Indexes jump: Dow 0.98%, S&amp;P 0.83%, Nasdaq 1.05%</li>\n</ul>\n<p>Oct 7 (Reuters) - Wall Street ended sharply higher on Thursday in a broad-based rally led by Big Tech, as a truce in the debt-ceiling standoff in the U.S. Congress relieved concerns of a possible government debt default this month.</p>\n<p>Mega-cap stocks jumped with Apple Inc&nbsp;up 0.9% and Amazon.com Inc&nbsp;rising 1.2%, the biggest boosts to the S&amp;P 500 and Nasdaq. Tesla&nbsp;and Google-parent Alphabet&nbsp;both rose more than 1%.</p>\n<p>The U.S. Senate took a step toward passing a $480 billion increase in Treasury Department borrowing authority, which would put off another partisan showdown until December.</p>\n<p>Uncertainty over the debt-ceiling negotiations was one concern investors cited in September as the S&amp;P 500 logged its biggest monthly percentage drop since the onset of the coronavirus pandemic in March 2020.</p>\n<p>\"Today's (market) is driven by a slight move in Washington towards rationality about being able to pay their bills, write some checks,\" said Kim Forrest, chief investment officer at Bokeh Capital Partners in Pittsburgh.</p>\n<p>Meanwhile, data showed the number of Americans filing new claims for jobless benefits dropped last week by the most in three months, suggesting the labor market recovery was regaining momentum as the latest wave of COVID-19 infections began to subside.</p>\n<p>The closely watched monthly U.S. jobs report is due on Friday.</p>\n<p>“Today’s numbers reinforce the expectation that employment will take a significant step up in the coming months, and I think that’s positive for the economy,” said Brad Neuman, director of market strategy at Alger.</p>\n<p>\"The market climbed its wall of worry today as fears of a debt-ceiling impasse receded and hopes for an acceleration in employment gains were reinforced.”</p>\n<p>The Dow Jones Industrial Average&nbsp;rose 0.98% to end at 34,754.94 points, while the S&amp;P 500&nbsp;gained 0.83% to 4,399.76.</p>\n<p>The Nasdaq Composite&nbsp;climbed 1.05% to 14,654.02.</p>\n<p>The S&amp;P 500 materials index&nbsp;jumped 1.35% and the consumer discretionary index&nbsp;rallied 1.50%, both leading among 11 sectors.</p>\n<p>U.S.-traded Chinese stocks Alibaba Group Holding&nbsp;and Tencent Holdings&nbsp;each surged about 8% as concerns around U.S.-Sino trade relations and Evergrande's&nbsp;debt crisis appeared to ease.</p>\n<p>Investors will watch third-quarter earnings reports that start to arrive in earnest next week. Analysts on average estimate S&amp;P 500 companies' earnings per share rose 29% in the third quarter, according to Refinitiv.</p>\n<p>Levi Strauss &amp; Co&nbsp;shares jumped 8.5% after the jeans maker beat third-quarter revenue and profit estimates.</p>\n<p>Volume on U.S. exchanges was 10.1 billion shares, compared with the 11 billion average over the last 20 trading days.</p>\n<p>Advancing issues outnumbered declining ones on the NYSE by a 2.50-to-1 ratio; on Nasdaq, a 2.49-to-1 ratio favored advancers.</p>\n<p>The S&amp;P 500 posted 31 new 52-week highs and four new lows; the Nasdaq Composite recorded 93 new highs and 80 new lows.</p>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Wall Street ends day with solid gains; investors hail U.S. debt-ceiling truce</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nWall Street ends day with solid gains; investors hail U.S. debt-ceiling truce\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1036604489\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/443ce19704621c837795676028cec868);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Reuters </p>\n<p class=\"h-time\">2021-10-08 06:49</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<ul>\n <li>U.S. Senate rushes to advance $480 bln debt-limit increase</li>\n <li>U.S. weekly jobless claims fall sharply</li>\n <li>Consumer discretionary and materials lead sectors</li>\n <li>Levi Strauss shares soar after profit beat</li>\n <li>Indexes jump: Dow 0.98%, S&amp;P 0.83%, Nasdaq 1.05%</li>\n</ul>\n<p>Oct 7 (Reuters) - Wall Street ended sharply higher on Thursday in a broad-based rally led by Big Tech, as a truce in the debt-ceiling standoff in the U.S. Congress relieved concerns of a possible government debt default this month.</p>\n<p>Mega-cap stocks jumped with Apple Inc&nbsp;up 0.9% and Amazon.com Inc&nbsp;rising 1.2%, the biggest boosts to the S&amp;P 500 and Nasdaq. Tesla&nbsp;and Google-parent Alphabet&nbsp;both rose more than 1%.</p>\n<p>The U.S. Senate took a step toward passing a $480 billion increase in Treasury Department borrowing authority, which would put off another partisan showdown until December.</p>\n<p>Uncertainty over the debt-ceiling negotiations was one concern investors cited in September as the S&amp;P 500 logged its biggest monthly percentage drop since the onset of the coronavirus pandemic in March 2020.</p>\n<p>\"Today's (market) is driven by a slight move in Washington towards rationality about being able to pay their bills, write some checks,\" said Kim Forrest, chief investment officer at Bokeh Capital Partners in Pittsburgh.</p>\n<p>Meanwhile, data showed the number of Americans filing new claims for jobless benefits dropped last week by the most in three months, suggesting the labor market recovery was regaining momentum as the latest wave of COVID-19 infections began to subside.</p>\n<p>The closely watched monthly U.S. jobs report is due on Friday.</p>\n<p>“Today’s numbers reinforce the expectation that employment will take a significant step up in the coming months, and I think that’s positive for the economy,” said Brad Neuman, director of market strategy at Alger.</p>\n<p>\"The market climbed its wall of worry today as fears of a debt-ceiling impasse receded and hopes for an acceleration in employment gains were reinforced.”</p>\n<p>The Dow Jones Industrial Average&nbsp;rose 0.98% to end at 34,754.94 points, while the S&amp;P 500&nbsp;gained 0.83% to 4,399.76.</p>\n<p>The Nasdaq Composite&nbsp;climbed 1.05% to 14,654.02.</p>\n<p>The S&amp;P 500 materials index&nbsp;jumped 1.35% and the consumer discretionary index&nbsp;rallied 1.50%, both leading among 11 sectors.</p>\n<p>U.S.-traded Chinese stocks Alibaba Group Holding&nbsp;and Tencent Holdings&nbsp;each surged about 8% as concerns around U.S.-Sino trade relations and Evergrande's&nbsp;debt crisis appeared to ease.</p>\n<p>Investors will watch third-quarter earnings reports that start to arrive in earnest next week. Analysts on average estimate S&amp;P 500 companies' earnings per share rose 29% in the third quarter, according to Refinitiv.</p>\n<p>Levi Strauss &amp; Co&nbsp;shares jumped 8.5% after the jeans maker beat third-quarter revenue and profit estimates.</p>\n<p>Volume on U.S. exchanges was 10.1 billion shares, compared with the 11 billion average over the last 20 trading days.</p>\n<p>Advancing issues outnumbered declining ones on the NYSE by a 2.50-to-1 ratio; on Nasdaq, a 2.49-to-1 ratio favored advancers.</p>\n<p>The S&amp;P 500 posted 31 new 52-week highs and four new lows; the Nasdaq Composite recorded 93 new highs and 80 new lows.</p>\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"LEVI":"李维斯",".DJI":"道琼斯",".IXIC":"NASDAQ Composite","AAPL":"苹果","AMZN":"亚马逊",".SPX":"S&P 500 Index","TSLA":"特斯拉","TCEHY":"腾讯控股ADR","BABA":"阿里巴巴"},"is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1163018074","content_text":"U.S. Senate rushes to advance $480 bln debt-limit increase\nU.S. weekly jobless claims fall sharply\nConsumer discretionary and materials lead sectors\nLevi Strauss shares soar after profit beat\nIndexes jump: Dow 0.98%, S&P 0.83%, Nasdaq 1.05%\n\nOct 7 (Reuters) - Wall Street ended sharply higher on Thursday in a broad-based rally led by Big Tech, as a truce in the debt-ceiling standoff in the U.S. Congress relieved concerns of a possible government debt default this month.\nMega-cap stocks jumped with Apple Inc up 0.9% and Amazon.com Inc rising 1.2%, the biggest boosts to the S&P 500 and Nasdaq. Tesla and Google-parent Alphabet both rose more than 1%.\nThe U.S. Senate took a step toward passing a $480 billion increase in Treasury Department borrowing authority, which would put off another partisan showdown until December.\nUncertainty over the debt-ceiling negotiations was one concern investors cited in September as the S&P 500 logged its biggest monthly percentage drop since the onset of the coronavirus pandemic in March 2020.\n\"Today's (market) is driven by a slight move in Washington towards rationality about being able to pay their bills, write some checks,\" said Kim Forrest, chief investment officer at Bokeh Capital Partners in Pittsburgh.\nMeanwhile, data showed the number of Americans filing new claims for jobless benefits dropped last week by the most in three months, suggesting the labor market recovery was regaining momentum as the latest wave of COVID-19 infections began to subside.\nThe closely watched monthly U.S. jobs report is due on Friday.\n“Today’s numbers reinforce the expectation that employment will take a significant step up in the coming months, and I think that’s positive for the economy,” said Brad Neuman, director of market strategy at Alger.\n\"The market climbed its wall of worry today as fears of a debt-ceiling impasse receded and hopes for an acceleration in employment gains were reinforced.”\nThe Dow Jones Industrial Average rose 0.98% to end at 34,754.94 points, while the S&P 500 gained 0.83% to 4,399.76.\nThe Nasdaq Composite climbed 1.05% to 14,654.02.\nThe S&P 500 materials index jumped 1.35% and the consumer discretionary index rallied 1.50%, both leading among 11 sectors.\nU.S.-traded Chinese stocks Alibaba Group Holding and Tencent Holdings each surged about 8% as concerns around U.S.-Sino trade relations and Evergrande's debt crisis appeared to ease.\nInvestors will watch third-quarter earnings reports that start to arrive in earnest next week. Analysts on average estimate S&P 500 companies' earnings per share rose 29% in the third quarter, according to Refinitiv.\nLevi Strauss & Co shares jumped 8.5% after the jeans maker beat third-quarter revenue and profit estimates.\nVolume on U.S. exchanges was 10.1 billion shares, compared with the 11 billion average over the last 20 trading days.\nAdvancing issues outnumbered declining ones on the NYSE by a 2.50-to-1 ratio; on Nasdaq, a 2.49-to-1 ratio favored advancers.\nThe S&P 500 posted 31 new 52-week highs and four new lows; the Nasdaq Composite recorded 93 new highs and 80 new lows.","news_type":1},"isVote":1,"tweetType":1,"viewCount":669,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0}],"lives":[]}